TW201034690A - Technetium-and rhenium-bis (heteroaryl) complexes and methods of use thereof for inhibiting PSMA - Google Patents
Technetium-and rhenium-bis (heteroaryl) complexes and methods of use thereof for inhibiting PSMA Download PDFInfo
- Publication number
- TW201034690A TW201034690A TW098141536A TW98141536A TW201034690A TW 201034690 A TW201034690 A TW 201034690A TW 098141536 A TW098141536 A TW 098141536A TW 98141536 A TW98141536 A TW 98141536A TW 201034690 A TW201034690 A TW 201034690A
- Authority
- TW
- Taiwan
- Prior art keywords
- compound
- integer
- group
- complex
- amine
- Prior art date
Links
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 title claims abstract description 27
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 title claims abstract description 25
- 238000000034 method Methods 0.000 title claims description 42
- 125000001072 heteroaryl group Chemical group 0.000 title description 7
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 title description 2
- 230000002401 inhibitory effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 116
- 210000001519 tissue Anatomy 0.000 claims abstract description 27
- 229910052751 metal Inorganic materials 0.000 claims abstract description 23
- 239000002184 metal Substances 0.000 claims abstract description 23
- 150000003839 salts Chemical class 0.000 claims abstract description 23
- 238000003384 imaging method Methods 0.000 claims abstract description 19
- 239000012453 solvate Substances 0.000 claims abstract description 19
- 230000002285 radioactive effect Effects 0.000 claims abstract description 14
- 229910052702 rhenium Inorganic materials 0.000 claims abstract description 7
- 229910052713 technetium Inorganic materials 0.000 claims abstract description 6
- -1 alkylammonium ion Chemical group 0.000 claims description 71
- 125000000217 alkyl group Chemical group 0.000 claims description 32
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 32
- 206010028980 Neoplasm Diseases 0.000 claims description 19
- 229910003827 NRaRb Inorganic materials 0.000 claims description 17
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine group Chemical group NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 16
- 229910021645 metal ion Inorganic materials 0.000 claims description 13
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 6
- 229910001420 alkaline earth metal ion Inorganic materials 0.000 claims description 5
- 229910052738 indium Inorganic materials 0.000 claims description 5
- 229910052727 yttrium Inorganic materials 0.000 claims description 5
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 229910001413 alkali metal ion Inorganic materials 0.000 claims description 3
- 125000005210 alkyl ammonium group Chemical group 0.000 claims description 3
- 229910052761 rare earth metal Inorganic materials 0.000 claims description 3
- 210000005084 renal tissue Anatomy 0.000 claims description 3
- 210000000952 spleen Anatomy 0.000 claims description 3
- 229910052802 copper Inorganic materials 0.000 claims 1
- 239000002689 soil Substances 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract description 14
- 102000004169 proteins and genes Human genes 0.000 abstract description 8
- 108090000623 proteins and genes Proteins 0.000 abstract description 8
- 201000010099 disease Diseases 0.000 abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
- 150000002739 metals Chemical class 0.000 abstract description 3
- 201000001514 prostate carcinoma Diseases 0.000 abstract 1
- WUAPFZMCVAUBPE-UHFFFAOYSA-N rhenium atom Chemical compound [Re] WUAPFZMCVAUBPE-UHFFFAOYSA-N 0.000 abstract 1
- GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 55
- 150000001412 amines Chemical class 0.000 description 43
- 239000002585 base Substances 0.000 description 41
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 26
- 239000002253 acid Substances 0.000 description 26
- 239000000243 solution Substances 0.000 description 23
- 239000002904 solvent Substances 0.000 description 22
- 239000000203 mixture Substances 0.000 description 21
- 239000011541 reaction mixture Substances 0.000 description 20
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 19
- 125000003118 aryl group Chemical group 0.000 description 19
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 19
- 239000007787 solid Substances 0.000 description 19
- 239000004202 carbamide Substances 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 16
- 239000000047 product Substances 0.000 description 16
- 238000011282 treatment Methods 0.000 description 16
- 125000004432 carbon atom Chemical group C* 0.000 description 15
- 238000005481 NMR spectroscopy Methods 0.000 description 14
- 206010060862 Prostate cancer Diseases 0.000 description 13
- 239000013078 crystal Substances 0.000 description 13
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 13
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 12
- 235000019439 ethyl acetate Nutrition 0.000 description 12
- 239000000463 material Substances 0.000 description 12
- 125000001424 substituent group Chemical group 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 230000027455 binding Effects 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 229910001868 water Inorganic materials 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 10
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 229910052799 carbon Inorganic materials 0.000 description 10
- 239000002738 chelating agent Substances 0.000 description 10
- 125000000753 cycloalkyl group Chemical group 0.000 description 10
- 229910052739 hydrogen Inorganic materials 0.000 description 10
- 239000001257 hydrogen Substances 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 10
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 9
- 125000000623 heterocyclic group Chemical group 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 8
- 125000003342 alkenyl group Chemical group 0.000 description 8
- 125000003545 alkoxy group Chemical group 0.000 description 8
- FXJKNCDSABKERB-UHFFFAOYSA-N ditert-butyl pentanedioate Chemical compound CC(C)(C)OC(=O)CCCC(=O)OC(C)(C)C FXJKNCDSABKERB-UHFFFAOYSA-N 0.000 description 8
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 8
- 239000003446 ligand Substances 0.000 description 8
- 239000012217 radiopharmaceutical Substances 0.000 description 8
- 229940121896 radiopharmaceutical Drugs 0.000 description 8
- 230000002799 radiopharmaceutical effect Effects 0.000 description 8
- 238000005160 1H NMR spectroscopy Methods 0.000 description 7
- OPVPGKGADVGKTG-BQBZGAKWSA-N Ac-Asp-Glu Chemical compound CC(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCC(O)=O OPVPGKGADVGKTG-BQBZGAKWSA-N 0.000 description 7
- 101150041968 CDC13 gene Proteins 0.000 description 7
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 7
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 description 7
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 7
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical class CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 125000004122 cyclic group Chemical group 0.000 description 6
- MWKFXSUHUHTGQN-UHFFFAOYSA-N decan-1-ol Chemical compound CCCCCCCCCCO MWKFXSUHUHTGQN-UHFFFAOYSA-N 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 125000005842 heteroatom Chemical group 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 125000003396 thiol group Chemical group [H]S* 0.000 description 6
- 239000000052 vinegar Substances 0.000 description 6
- 235000021419 vinegar Nutrition 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 5
- WDJHALXBUFZDSR-UHFFFAOYSA-N acetoacetic acid Chemical compound CC(=O)CC(O)=O WDJHALXBUFZDSR-UHFFFAOYSA-N 0.000 description 5
- 125000000304 alkynyl group Chemical group 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 239000013522 chelant Substances 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 238000001704 evaporation Methods 0.000 description 5
- 125000000524 functional group Chemical group 0.000 description 5
- 229910052736 halogen Inorganic materials 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 150000003573 thiols Chemical class 0.000 description 5
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 4
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 4
- AHLWZBVXSWOPPL-RGYGYFBISA-N 20-deoxy-20-oxophorbol 12-myristate 13-acetate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(C=O)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C AHLWZBVXSWOPPL-RGYGYFBISA-N 0.000 description 4
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 241001602688 Pama Species 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- 206010036790 Productive cough Diseases 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 150000002367 halogens Chemical class 0.000 description 4
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 4
- 239000013067 intermediate product Substances 0.000 description 4
- 150000002576 ketones Chemical class 0.000 description 4
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 4
- 230000008520 organization Effects 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 125000004076 pyridyl group Chemical group 0.000 description 4
- 239000011535 reaction buffer Substances 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 210000003802 sputum Anatomy 0.000 description 4
- 208000024794 sputum Diseases 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 3
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 241001397104 Dima Species 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- 230000009137 competitive binding Effects 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 3
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 3
- 150000002431 hydrogen Chemical class 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 239000012216 imaging agent Substances 0.000 description 3
- 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 150000002923 oximes Chemical class 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 125000003367 polycyclic group Chemical group 0.000 description 3
- 210000002307 prostate Anatomy 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 125000003226 pyrazolyl group Chemical group 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 238000004007 reversed phase HPLC Methods 0.000 description 3
- 229910052707 ruthenium Inorganic materials 0.000 description 3
- 210000003296 saliva Anatomy 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical group CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- VZXTWGWHSMCWGA-UHFFFAOYSA-N 1,3,5-triazine-2,4-diamine Chemical compound NC1=NC=NC(N)=N1 VZXTWGWHSMCWGA-UHFFFAOYSA-N 0.000 description 2
- NKTDTMONXHODTI-UHFFFAOYSA-N 2-pentyne Chemical compound CCC#CC NKTDTMONXHODTI-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 239000002879 Lewis base Substances 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 2
- 239000002262 Schiff base Substances 0.000 description 2
- 150000004753 Schiff bases Chemical class 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229910000831 Steel Inorganic materials 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- KDKYADYSIPSCCQ-UHFFFAOYSA-N but-1-yne Chemical compound CCC#C KDKYADYSIPSCCQ-UHFFFAOYSA-N 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 239000013058 crude material Substances 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- YVXHZKKCZYLQOP-UHFFFAOYSA-N hept-1-yne Chemical compound CCCCCC#C YVXHZKKCZYLQOP-UHFFFAOYSA-N 0.000 description 2
- 125000002632 imidazolidinyl group Chemical group 0.000 description 2
- 125000002636 imidazolinyl group Chemical group 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000001361 intraarterial administration Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 150000007527 lewis bases Chemical class 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 229960005181 morphine Drugs 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 125000006574 non-aromatic ring group Chemical group 0.000 description 2
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- 150000004032 porphyrins Chemical class 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 238000000163 radioactive labelling Methods 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- WOCIAKWEIIZHES-UHFFFAOYSA-N ruthenium(iv) oxide Chemical compound O=[Ru]=O WOCIAKWEIIZHES-UHFFFAOYSA-N 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000010959 steel Substances 0.000 description 2
- 230000002739 subcortical effect Effects 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 150000003456 sulfonamides Chemical class 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 125000001425 triazolyl group Chemical group 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- PSLCKQYQNVNTQI-BHFSHLQUSA-N (2s)-2-aminobutanedioic acid;(2s)-2-aminopentanedioic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O.OC(=O)[C@@H](N)CCC(O)=O PSLCKQYQNVNTQI-BHFSHLQUSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- YJTKZCDBKVTVBY-UHFFFAOYSA-N 1,3-Diphenylbenzene Chemical group C1=CC=CC=C1C1=CC=CC(C=2C=CC=CC=2)=C1 YJTKZCDBKVTVBY-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- CGHIBGNXEGJPQZ-UHFFFAOYSA-N 1-hexyne Chemical compound CCCCC#C CGHIBGNXEGJPQZ-UHFFFAOYSA-N 0.000 description 1
- HBXWUCXDUUJDRB-UHFFFAOYSA-N 1-octadecoxyoctadecane Chemical class CCCCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCCCC HBXWUCXDUUJDRB-UHFFFAOYSA-N 0.000 description 1
- IBXNCJKFFQIKKY-UHFFFAOYSA-N 1-pentyne Chemical compound CCCC#C IBXNCJKFFQIKKY-UHFFFAOYSA-N 0.000 description 1
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
- YHDRDWFCBXNYDM-UHFFFAOYSA-N 2-(trifluoromethoxycarbonyl)benzoic acid Chemical compound C1=CC=C(C(=C1)C(=O)O)C(=O)OC(F)(F)F YHDRDWFCBXNYDM-UHFFFAOYSA-N 0.000 description 1
- UVININLYSAHIFI-UHFFFAOYSA-N 2-[[2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl]amino]acetic acid Chemical compound CC(C)(C)OC(=O)CNCC(O)=O UVININLYSAHIFI-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- CSDSSGBPEUDDEE-UHFFFAOYSA-N 2-formylpyridine Chemical compound O=CC1=CC=CC=N1 CSDSSGBPEUDDEE-UHFFFAOYSA-N 0.000 description 1
- VTWDKFNVVLAELH-UHFFFAOYSA-N 2-methylcyclohexa-2,5-diene-1,4-dione Chemical compound CC1=CC(=O)C=CC1=O VTWDKFNVVLAELH-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- DQQNMIPXXNPGCV-UHFFFAOYSA-N 3-hexyne Chemical compound CCC#CCC DQQNMIPXXNPGCV-UHFFFAOYSA-N 0.000 description 1
- CNPURSDMOWDNOQ-UHFFFAOYSA-N 4-methoxy-7h-pyrrolo[2,3-d]pyrimidin-2-amine Chemical compound COC1=NC(N)=NC2=C1C=CN2 CNPURSDMOWDNOQ-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 description 1
- 101100027969 Caenorhabditis elegans old-1 gene Proteins 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- 102000005572 Cathepsin A Human genes 0.000 description 1
- 108010059081 Cathepsin A Proteins 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229910021580 Cobalt(II) chloride Inorganic materials 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 102000004860 Dipeptidases Human genes 0.000 description 1
- 108090001081 Dipeptidases Proteins 0.000 description 1
- 230000010665 Enzyme Interactions Effects 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 239000007821 HATU Chemical group 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000999322 Homo sapiens Putative insulin-like growth factor 2 antisense gene protein Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 244000294411 Mirabilis expansa Species 0.000 description 1
- 235000015429 Mirabilis expansa Nutrition 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 102000003797 Neuropeptides Human genes 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102100036485 Putative insulin-like growth factor 2 antisense gene protein Human genes 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 206010070308 Refractory cancer Diseases 0.000 description 1
- 239000012327 Ruthenium complex Substances 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical group [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000003302 alkenyloxy group Chemical group 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 125000005133 alkynyloxy group Chemical group 0.000 description 1
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 description 1
- 235000008206 alpha-amino acids Nutrition 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 1
- 229910001863 barium hydroxide Inorganic materials 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- SIKJAQJRHWYJAI-UHFFFAOYSA-N benzopyrrole Natural products C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 1
- 239000012964 benzotriazole Substances 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- JSMRMEYFZHIPJV-UHFFFAOYSA-N bicyclo[2.1.1]hexane Chemical compound C1C2CC1CC2 JSMRMEYFZHIPJV-UHFFFAOYSA-N 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000008081 blood perfusion Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- NWJBOTGGBYFKEJ-UHFFFAOYSA-M bromorhenium;carbon monoxide Chemical compound [O+]#[C-].[O+]#[C-].[O+]#[C-].[O+]#[C-].[O+]#[C-].[Re]Br NWJBOTGGBYFKEJ-UHFFFAOYSA-M 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 125000004181 carboxyalkyl group Chemical group 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229910000420 cerium oxide Inorganic materials 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 150000001844 chromium Chemical class 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 150000004696 coordination complex Chemical class 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 150000003983 crown ethers Chemical class 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000004643 cyanate ester Substances 0.000 description 1
- 150000001913 cyanates Chemical class 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 150000004292 cyclic ethers Chemical class 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000000000 cycloalkoxy group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- LMEDOLJKVASKTP-UHFFFAOYSA-N dibutyl sulfate Chemical compound CCCCOS(=O)(=O)OCCCC LMEDOLJKVASKTP-UHFFFAOYSA-N 0.000 description 1
- ZFTFAPZRGNKQPU-UHFFFAOYSA-N dicarbonic acid Chemical compound OC(=O)OC(O)=O ZFTFAPZRGNKQPU-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- VVFLLIOBIOXECC-UHFFFAOYSA-N diphenylmethanone;sulfuric acid Chemical compound OS(O)(=O)=O.C=1C=CC=CC=1C(=O)C1=CC=CC=C1 VVFLLIOBIOXECC-UHFFFAOYSA-N 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 150000002081 enamines Chemical class 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- CEIPQQODRKXDSB-UHFFFAOYSA-N ethyl 3-(6-hydroxynaphthalen-2-yl)-1H-indazole-5-carboximidate dihydrochloride Chemical compound Cl.Cl.C1=C(O)C=CC2=CC(C3=NNC4=CC=C(C=C43)C(=N)OCC)=CC=C21 CEIPQQODRKXDSB-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 229910052733 gallium Inorganic materials 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- KLYHSJRCIZOUHE-UHFFFAOYSA-N hept-3-yne Chemical compound CCCC#CCC KLYHSJRCIZOUHE-UHFFFAOYSA-N 0.000 description 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
- 125000005844 heterocyclyloxy group Chemical group 0.000 description 1
- MELUCTCJOARQQG-UHFFFAOYSA-N hex-2-yne Chemical compound CCCC#CC MELUCTCJOARQQG-UHFFFAOYSA-N 0.000 description 1
- ZILMEHNWSRQIEH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O.CCCCCC(O)=O ZILMEHNWSRQIEH-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 102000046689 human FOLH1 Human genes 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 150000007857 hydrazones Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229910000040 hydrogen fluoride Inorganic materials 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000027056 interspecies interaction between organisms Effects 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 235000013536 miso Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- BAVYZALUXZFZLV-UHFFFAOYSA-N mono-methylamine Natural products NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004957 naphthylene group Chemical group 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000003961 neuronal insult Effects 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000009206 nuclear medicine Methods 0.000 description 1
- QCQALVMFTWRCFI-UHFFFAOYSA-N oct-2-yne Chemical compound CCCCCC#CC QCQALVMFTWRCFI-UHFFFAOYSA-N 0.000 description 1
- UDEISTCPVNLKRJ-UHFFFAOYSA-N oct-3-yne Chemical compound CCCCC#CCC UDEISTCPVNLKRJ-UHFFFAOYSA-N 0.000 description 1
- GZTNBKQTTZSQNS-UHFFFAOYSA-N oct-4-yne Chemical compound CCCC#CCCC GZTNBKQTTZSQNS-UHFFFAOYSA-N 0.000 description 1
- RZJRJXONCZWCBN-UHFFFAOYSA-N octadecane Chemical compound CCCCCCCCCCCCCCCCCC RZJRJXONCZWCBN-UHFFFAOYSA-N 0.000 description 1
- GLZWNFNQMJAZGY-UHFFFAOYSA-N octaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCOCCOCCO GLZWNFNQMJAZGY-UHFFFAOYSA-N 0.000 description 1
- 229910052762 osmium Inorganic materials 0.000 description 1
- SYQBFIAQOQZEGI-UHFFFAOYSA-N osmium atom Chemical compound [Os] SYQBFIAQOQZEGI-UHFFFAOYSA-N 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- BMMGVYCKOGBVEV-UHFFFAOYSA-N oxo(oxoceriooxy)cerium Chemical compound [Ce]=O.O=[Ce]=O BMMGVYCKOGBVEV-UHFFFAOYSA-N 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- JQQSUOJIMKJQHS-UHFFFAOYSA-N pentaphenyl group Chemical group C1=CC=CC2=CC3=CC=C4C=C5C=CC=CC5=CC4=C3C=C12 JQQSUOJIMKJQHS-UHFFFAOYSA-N 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- ACVYVLVWPXVTIT-UHFFFAOYSA-N phosphinic acid Chemical compound O[PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 150000004060 quinone imines Chemical class 0.000 description 1
- 150000004053 quinones Chemical class 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 208000016691 refractory malignant neoplasm Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000004492 retinoid derivatives Chemical class 0.000 description 1
- 150000003304 ruthenium compounds Chemical class 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical group O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 150000003385 sodium Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 229910052712 strontium Inorganic materials 0.000 description 1
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
- 125000005017 substituted alkenyl group Chemical group 0.000 description 1
- 125000005415 substituted alkoxy group Chemical group 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 description 1
- NYBWUHOMYZZKOR-UHFFFAOYSA-N tes-adt Chemical class C1=C2C(C#C[Si](CC)(CC)CC)=C(C=C3C(SC=C3)=C3)C3=C(C#C[Si](CC)(CC)CC)C2=CC2=C1SC=C2 NYBWUHOMYZZKOR-UHFFFAOYSA-N 0.000 description 1
- 150000000000 tetracarboxylic acids Chemical class 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000005888 tetrahydroindolyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000002769 thiazolinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 150000003567 thiocyanates Chemical class 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 150000007944 thiolates Chemical class 0.000 description 1
- 238000003971 tillage Methods 0.000 description 1
- 125000005147 toluenesulfonyl group Chemical group C=1(C(=CC=CC1)S(=O)(=O)*)C 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 229960004441 tyrosine Drugs 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
- C07C275/06—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
- C07C275/16—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
- C07F13/005—Compounds without a metal-carbon linkage
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Quinoline Compounds (AREA)
- Peptides Or Proteins (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Description
201034690 六、發明說明: 【發明所屬之技術領域】 參考相關申請案 本案請求美國臨時專利申請案第61/12〇 226號,申請曰 2008年12月5日及第61/180,341號,申請日2〇〇9年5月21日之 權益,二案全文皆係以引用方式併入此處用於任何及全部 目的。 發明領域 Ο
本發明大致上係關於放射性藥品領域及其用於核子醫 學作為追蹤劑、顯像劑及用於多種疾病病情之治療之用 途。眾所周知腫瘤可能表現與其惡性表現型相關聯之獨特 蛋白質,或可能比正常細胞更大量地過度表現正常組成蛋 白質。於腫瘤細胞表面之獨特蛋白質的表現提供經由探測 腫瘤之表現型身分及生化組成及活性而提供診斷疾病及特 徵化疾病的機會。選擇性地結合至特定腫瘤細胞表面蛋白 質之放射性分子提供於非侵入性條件下用以顯像及治療腫 瘤之具有吸引力的途徑。特定言之,發明人發現對經常過 度表現於許多腫瘤細胞上之PSMA蛋白質之經放射性標士己 的配體提供癌細胞之非侵入性顯像及選擇性靶定之具有〇及 引力的途徑。 t先前技術】 發明背景 美國至少有一百萬名男性患有攝護腺癌,估計該疾病 將攻擊60歲至80歲美國男性每六位中之一位。每年新診斷 3 201034690 出之攝護腺癌病例超過三十萬例。美國男性攝護腺癌患者 佔六分之一,因此導致之死亡率僅次於肺癌名列第二。全 球每年花費在手術、放射線治療、藥物治療及最低侵入性 治療之費用估計達二十萬美金,美國每年花費十億美金。 目前並無可用於復發性、轉移性、雄激素非依賴性攝護腺 癌的有效治療。需要有可允許攝護腺癌快速視覺偵測及專 一性靶定來允許做放射線治療之新穎化學劑。 N-乙醯化〇c鏈接酸性二肽酶(NAALADase)也稱作為麩 胺酸羧肽酶II(GCPII)為於神經系統可將N-乙醯基天冬醯基 -麩胺酸NAAG裂解成N-乙醯基天冬酸酯及麩胺酸酯之神經 肽酶,參見後文說明藉NA ALDase透過四面體中間產物進行 NAAG之水解裂解。酶為活性部位含有兩個鋅原子之金屬 肽酶之共同催化類別之II型蛋白質。
與其於神經系統之特徵獨立無關,顯示一種形式之 NAALADase可以高濃度於人攝護腺癌表現,定名為攝護腺 專一性膜抗原(PSMA)。NAALADase/PSMA基因已知可製造 多個mRNA截割形式,及基於先前免疫組織化學證據,已 經假設人腦及攝護腺可表現不同的酶之同質異形體。 人攝護腺專一性膜抗原(P S Μ A )也稱作為葉酸水解 I(FOLHl)屬於一種穿膜750胺基酸II型糖蛋白,主要表現於 201034690 正常人攝護腺上皮,但於攝護腺癌包括轉移癌向上升高。 PSMA為對夕个麵胺酸化葉酸具有反應性,可循序移除多 Y麵胺醯基終端之獨特胜肽外切酶。由於係由實質 上王顿遵腺癌表現,及於不良分化的轉移性及激素頑固 癌瘤中更進-步升〶’故PSMA為攝護腺顯像及治療上極為 具有吸弓I力的標乾。與PSMA交互作用且攜帶適當放射性核 種之發展中的配體可提供用於攝護腺癌之檢測、治療及管 理上具有展望性且新穎的靶定選項。 〇 ' 抗-PSMA單株抗體(mAb)7El 1稱作為攝護腺閃爍 (PROSTASCINT)掃描之放射性免疫軛合物形式目前用於診 斷攝護腺癌的轉移及復發。更為晚近,發展出單株抗體, ,其係結合至PSMA之胞外功能部位且已經經放射性標記而 顯示累積於動物體内之PSMA陽性攝護腺腫瘤研究模型。 雖然單株抗體用於腫瘤之檢測及治療上有展望,但於 淋巴瘤以外的領域臨床上的成功有限,原因在於其穿透實 ^ 體腫瘤之通透度低。具有實體腫瘤較高通透度之低分子量 模擬物用於獲得每克百分比高及專一性結合百分比高方面 確切具有優勢。 以放射性藥品選擇性靶定於癌細胞’無論係用於顯像 或治療目的皆具有挑戰性。已知多種放射性核種可用於放 射性顯像,包括Ga-67、Tc-99m、In-111、1-123、及 1-131。 較佳用於醫療顯像之放射性同位素為Tc_99m,原因在於其 半衰期短(6小時),易以相對低成本取得及發射140KeV之γ 光子。此外,Tc-99m錯合物諸如水及空氣穩定性Tc(〗)錯合 5 201034690 物[99mTc(OH2)3(CO)3]+錯合物易於一大氣壓一氧化碳(c〇) 下於鹽水中製備。 【發明内容】 發明概要 於一個面相,提供一種式I化合物或其藥學上可接受之 鹽或溶劑合物:
〇 〇 此處:R為Η、銨離子、烷基銨離子、鹼土金屬離子、稀土 金屬離子、或烷基;W為鍵結、-NHC(O)-、-CH(NH2)-、 -NH-C(O0-NH_ ' _C(0)-NH-、-C(0)-NH-CH(C00H)_、 -0-(CH2)n-0-(CH2)n- 、 -(CH2)nO(CH2)nO(CH2)n-、 -CH(NHFmoc)- ; Z為鍵結、-CO(O)-、-NH-、-NHC(O)-、 -NH-C(0)-NH- ' -NH-C(0)-(CH2)n-、-NH-C(0)-CH(NH2)-、 -C(0)-NH-CH(C00H)-;或-NH-C(0)-C6H4-(CH2)n-NH-; NRaRb為下式螯合基:
201034690
0
RtiOC
RtQOC 或 R{〇2〇~\ /~\ //~C02Rt
以為!!、CVCs烷基、銨離子、烷基銨離子、或鹼金屬離子 或鹼土金屬離子;Rv為烷基、經取代之胺烷基、胺烷基、 或乙醯胺烷基;e為0至15之整數;f為0至15之整數;g為0 至15之整數;及η為0至10之整數;但限制條件為若NRaRb
則當W為鍵結時,Z非為鍵結、-C(0)-NH-、或-NHC(O)-; 及當Z為鍵結時,W非為鍵結、-C(0)-NH-、或-NHC(O)-。 於若干實施例中,Rv為曱基、乙基、正丙基、異丙基、 正丁基、異丁基、第三丁基、胺烷基、羥烷基、或羧烷基。 於若干實施例中,Rv為甲基。於若干實施例中,各個以分 7 201034690 別為Η或第三丁基。於若干實施例中,1^為11。於若干實施 例中,e為0至4之整數,f為0至12之整數,及g為0至6之整 數。於若干實施例中,W為-C(0)-NH-。 於若干實施例中,式I化合物為:
201034690
9 201034690
p c02h N C〇2H H H〇2C^n n^co2h
其藥學上可接受之鹽或溶劑合物;e為〇至l〇之整數;f為0 至12之整數;g為0至12之整數;及η為0至10之整數。 於若干實施例中,Ζ為-NH-C(o)-。於若干實施例中,ζ 為-C(0)-NH-CH(C00H)-。於若干實施例中,Z為 -nh-c(o)-ch(nh2)-。 於另一個面相,提供包括金屬及式Σ化合物之錯合物。 於若干實施例中,金屬為Re、Tc、Y、Lu、Ga、In、或CU。 於若干實施例中,金屬為放射性核種。於若干實施例中, 金屬為搭-99m、銖-186、或鍊_i88。
或Cu’此處錯合物包括呈下式基團之NRaRb:
於若干實施例中’該錯合物為: 10 201034690
NH
ο Ο COOH
11 201034690
HO
12 201034690 其藥學上可接受之鹽或溶劑合物;此處Μ為Re、TC、Y、lu
整數;及η為〇至1〇之整數。 於另一個面相,提供包括式j化合物、其藥學上可接受 之鹽或溶劑合物及藥學上可接受之賦形劑之藥學配方。 於另一個面相,提供一種顯像病人體之一區之方法包 括對該病人投予診斷上有效量之式〗化合物、其藥學上可接 ^:之鹽或溶劑合物,及獲得該病人該區之影像。 於另一個面相,提供一種顯像組織諸如脾組織、腎組 織、或PSMA·表現性腫瘤組織之方法,包括讓該組織接觸 包括放射性金屬及包括下式化合物··
其藥學上可接受之鹽或溶劑合物之錯合物。於若干實施例 中’該組織為PSMA表現性腫瘤組織。於其它實施例中,該 PSMA表現性腫瘤組織為攝護腺癌。 圖式簡單說明 第1圖為實例3化合物之99mTc錯合物於LNCaP異種移植 小鼠之組織分布圖,以%DPO表示。 弟2圖顯示比較性及說明性根據式I化合物對ρ^μα蛋 13 201034690 白質之競爭結合曲線。 第3圖為實例8化合物之99mTc錯合物之組織分布圖,以 %ID/克表示。 第4圖為實例7化合物之99mTc錯合物之組織分布圖,以 %ID/克表示。 第5圖為99mTc錯合物於LNCaP異種移植小鼠之組織生 物分布之比較圖,以°/〇ID/克表示。 第6圖為影像示例顯示於各個時間間隔及根據若干實 施例實例6化合物之99mTc錯合物於LNCaP異種移植小鼠之 組織生物分布。 I:實施方式3 較佳實施例之詳細說明 有兩大類放射性藥品:(i)具有嚴格藉血流或灌流決定 之生物分布且乾定於高容量系統諸如腎小球過濾、吞噬作 用、肝細胞清除及骨質吸收之該等放射性藥品及(Η)具有由 專一性酶交互作用或受體結合交互作用所決定之分布之該 等放射性藥品,此等部位為低容量部位。本放射性藥品屬 於第二類及係經由將放射性核種配位錯合物軛合至對感興 趣之特定蛋白質或受體具有選擇性之生物活性分子合成。 雖然多種生物活性分子(BAM)可用作為載劑,但小分 子及小胜肽具有優於抗體或蛋白質之優點。舉例言之,小 刀子及小胜肽具有較高擴散性、較快速血液清除率、及較 低背景㈣。此等制允許以高產出量方式合成類似物。 此外,小胜狀容易轉換成胜肽模擬物或小分子類似物其具 201034690 有較高安定性及對標耙酶或受體有改良之親和力。 於一個面相,提供根據式Ϊ至式r^iPSMA選擇性鍀及 銖錯合物作為用於癌細胞之治療及顯像之新穎放射性藥品 之合成及使用方法。特定言之,該等化合物可用於靶定攝 護腺癌。
NRaRb 定義 為求方便,此處採用之及落入於隨附之申請專利範圍 之若干術語集合於此處。
如此處使用’「約」為熟諳技藝人士所瞭解且依據其使 用之上下文將改變至某餘度。若該術語之料對熟諸技 藝人士為未明,於使用該術語之給定上下文中,「約」將表 示》亥特定術5吾之至多加或減1 〇%。 只w π艰δ π此匙禾特別揭示之任柄 π件或限制存在下進行。如此,例如「包含」 :二:以::方式解讀㈣限制性。此外,此處採: :及表料仙作為描述性術語而魏制性 構㈣用中排除其所示及所述特徵- 内可做_修改。此外,「主要=求專利之 瞭解包括_⑽之該等元體及不 牵—詞須 術之基本特性及 θ對本案所清求專利技 及新靖特性造成實質影響之該等額外 201034690 「包含」一詞排除未载明的任何元體。 「一」及「該」及於描述元體之上下文中(特別於如下 申請專利㈣之上下文中之類似㈣)須解料涵蓋單數 及複數,除祕此處特示或藉上下文有清晰的矛盾陳 述。 如此處使用「親脂基團」及「親脂部分」等詞係指對 非極性及非水性環境她於雜性或水性環境有較大親和 力之基團4分或取代基。例如Merriam Webster之線上詞 ^義「親脂性」為「對脂質(呈脂肪)具有親和力」。親脂 邛刀之實例包括脂肪族烴基例如烷基芳香烴基、及長鏈 =基’隨著組成碳數的增加,全部皆具有較高親脂性。通 ^添加親脂部分至特定化合物將增高於標準辛醇/水 分溶 案中該化合物對辛醇之親和力;此種方案可用 ;十量化合物的相對斥水性(親脂性)及親水性。 路易士驗」及「路易士鹼性」等詞係指於某些反應 条件下可給對電子之化學部分。可將路易士驗特徵化 為依據路易士驗及金屬離子之身分而定 ,於某些錯合物中 給予單—雷工 s 更子’但最瞭解作為二電子施體之路易士鹼。路 胺@11 分實例包括未帶電化合物諸如醇類、硫醇類及 子類,▼電部*諸如&氧陰料類、硫醇酸根類、碳陰離 單夕種其匕有機陰離子。於若干實例中’路易士驗包含 & 如氧陰離子(〇2') °於若干較不常見的情況下, 易士鹼或配體可帶正電。路易士驗當配位至金屬離子時 _詞係指以某種方式與另—個種類交 16 201034690 互作用之種類。於一個實例中,配體可為路易士驗,其可 與路易士酸形成配位鍵。於其它實施例中,配體為與金屬 離子形成配位鍵之種類經常為有機。配體當配位至金屬離 子時具有多種熟諳技藝人士已知之結合模式,例如包括端 末(亦即結合至單一金屬離子)及橋接(亦即一個路易士鹼結 合至多於一個金屬離子)。
「螯合劑」一詞係指有兩個或多個未共享電子可供給 予金屬離子之分子,經常為有機分子且常為路易士鹼。金 屬離子通常係藉兩個或多個電子對而配位至螯合劑。「二齒 螯合劑」、「三齒螯合劑」、及「四齒螯合劑」為技藝界所瞭 解且係指分別具有二、三及四電子對方便同時給予由該聲 合劑配位的金屬離子之螯合劑。通常,螯合劑之電子對係 與單一金屬離子形成配位鍵;但於某些實例中,螯合鋼可 與多於一個金屬離子形成配位鍵,多種結合模式皆屬可能。 「配位」一詞係指其中一個多電子對施體配位鍵結(也 稱作為「配位」)至一個金屬離子之交互作用。 「錯合物」一詞係指經由可獨立存在之一個或多個舍 電子及乏電子分子或原子與各自也可獨立存在之一個或= 個電子缺乏分子聯合所形成之化合物。
Fmoc為化學基:芴基甲基氧羰基之縮寫。 如此處使用「治療上有效量」一詞表示化合物、材料 或包含該化合物之組成物可有效用於動物體内至少一 細 胞次族群以可應用於任何醫療處理上合理的效益/風險匕 用來產生某種期望的療效之數量。 17 201034690 如此處使用「治療」或「處理」等詞意圖也涵蓋診斷、 預防、療法及治癒。接受此項處理之病人可為任何有需要 之動物包括靈長類,特別為人類及其它哺乳動物諸如馬 牛、豬、及綿羊;及通稱家禽及寵物。 樂学上可接受 ,认八,」 -------。曰哆寻化合物、 材料組成物及/或劑型其於聲度醫學判定範圍内,適人用於 接觸人類及動作組織而無過度毒性、刺激性、過敏反應或 其它問題或併發症與合理的效益/風險比相稱。 如此處使用「藥學上可接受之載劑」—詞表示藥學上 可接受之材料、組成物或載媒劑,諸如液體或固體填充劑、 稀釋劑、賦形劑或溶劑包囊材料涉及自一個器官或身體部 分攜帶或轉運主題化合物至身體之另一個器官或另 分。各個載劑必須為「可接受性」表示與該調配物中之^ 它成分可相容且不會對病人造成傷害。可用作為華學上 接受之载劑之若干材料實例包括:⑴糖類諸如乳糖、葡萄 糖及庶糖;(2)澱粉諸如玉米澱粉 物及馬鈴核粉;(3)纖維素 物諸如射基纖維素鈉、乙基纖維素及乙酸纖維 素,⑷粉狀西黃蓍膠;(5)麥芽;⑹明 可可脂及峨,油類諸如花生油、: 紅化籽油、芝麻油、撖欖油、 類諸如油;(1〇)二醇 醇及嗲乙-扩 %類诸如甘油、山梨糖醇、甘露糖 2)㈣諸如及月桂H⑼ 糖’(14)緩衝_如氫氧化 〇6)不含Μ原水.Π7^ $魏化1呂,〇5)滅蛋白酸; …原水’⑼專張鹽水;⑽ 201034690 醇;(20)pH緩衝液;(21)聚酯類、聚碳酸酯類及/或聚酐類; 及(22)用於藥學配方中之其它無毒可相容物質。 如此處使用「腸道外投予」及「經腸道外投藥」等詞 表示腸道投藥及局部投藥以外之投予模式,通常係藉注射 及包括但非限於靜脈、肌肉、動脈内 '鞘内、囊内、眶内、 〜内皮内、腹内、經氣管、皮下、角質層下、關節内、 囊下、纟知蛛骐下、椎骨内及胸骨内注射/輸注。 ^ 「系統性投予」、「經系統地投予」、「周邊投予」及「經 周邊技予」等詞用於此處表示化合物、藥物或其它材料直 接投予中樞神經系統以外之投藥,諸如進入病人系統,如 此接受代謝或其它類似的處理程序例如皮下投予。 . 胺基酸」一詞涵蓋包括二官能基及酸官能基之全部 • 化合物,無論為天然或合成,包括胺基酸類似物及衍生物。 「 雜原子」一詞係指碳或氫以外之任何元素原子。雜 原子之實例包括硼、氮、氧、磷、硫及硒。 〇 概略言之,「經取代之」係指如後文定義之烷基或烯基 (例如烧基)其中鍵結至其中所含氫料之—個或多個鍵係 由鍵、纟°至非氫或非碳原子之鍵結所置換。經取代之基團也 包括其中鍵結至碳或氫原子之一個或多個鍵係由鍵結至雜 原子之—個或多個鍵包括雙鍵或參鍵所置換。如此除非另 行規疋,否則經取代之基團將以一個或多個取代基取代。 於若干實施例中’經取代之基團係以1、2、3、4、5、或6 個取代基取代)。取代基之實例包括:鹵素(亦即F、Cb Br、 及D ;羥基;烷氧基;烯氧基;炔氧基;芳氧基;芳烷氧基; 19 201034690 雜環基氧基,及雜環基烷氧基;羰基(酮基);羧基;酯類; 胺甲酸醋類,_;經基胺類;烧氧胺類;芳烧氧胺類; 硫醇類,硫化物類;亞砜類;颯類;磺醯基;磺醯胺類; 胺類;N-氧化物類;肼類;醯肼類;腙類;疊氮化物類; 醯胺類;脲類;眯類;胍類;烯胺類;醯亞胺類;異氰峻 酯類;異硫氰酸酯類;氰酸酯類;硫氰酸酯類;亞胺類; 硝基;腈類(亦即CN)等。 烷基包括有1至12個碳原子及典型丨至10個碳原子或於 若干實施例中,1至8、丨至6、或丨至4個碳原子之直鏈及分 支鏈烷基。直鏈烷基之實例包括諸如甲基、乙基、正丙基、 正丁基、正戊基、正己基' 正庚基、及正辛基。分支垸基 之實例包括但非限於異丙基、異丁基 '第二丁基' 第三丁 基、新戊基、異戊基、及2,2-二曱基丙基。烷基可經取代或 未經取代。除非另行載明碳數,否則「低碳炫基」係指如 月il文定義但具有1至約1 〇個碳,另外1至約6個碳原子於其主 鏈結構之燒基。同理,「低碳烯基」及「低碳炔基」具有類 似的鏈長度。 「烷基羰基」一詞表示其中於(^-(:8烷基中之一個或多 個亞甲基經以C(O)基置換之-(CrC8)烷基-C(0)基。代表例 包括但非限於乙醯基、丙醯基、及CH3(CH2)2C(〇)_基。 「環狀烷基」或「環烷基」等詞係指含3至14個碳原子 而不含環雜原子且具有單一個環或多個環包括稠合環系及 橋接環系之飽和或部分飽和非芳香族環狀院基。環炫基^]· 經取代或未經取代。環烧基或環狀烧基包括環中有3至14個 20 201034690 碳原子或於若干實施例中,3至12、3至10、3至8、或3至4、 5、6或7個碳原子之一環、二環或三環烷基。一環環烷基之 實例包括但非限於環丙基、環丁基、環戊基、環己基、環 庚基、及環辛基。二環及三環環系包括橋接環烷基及稠合 環諸如但非限於二環[2.1.1]己烷、金剛烷基、十氫萘基等。 烯基包括如前文定義之直鏈及分支鏈及環烷基,但兩 個碳原子間至少存在有一個雙鍵。如此,烯基於若干實施 例中具有2至約12個碳原子’於其它實施例中,2至10個碳 原子及於其它實施例中2至8個碳原子。實例包括但非限於 乙烯基、烯丙基、-ch=ch(ch3)、-ch=c(ch3)2、 -C(CH3)=CH2、-C(CH3)=CH(CH3)、-C(CH2CH3)=CH2、環己 烯基、環戊烯基、環己二烯基、丁二烯基、戊二烯基、及 己二烯基等。烯基可經取代或未經取代。代表性之經取代 之烯基可經一取代或經多於一次取代,諸如但非限於經以 諸如前文列舉之取代基一_、二_或三_取代。 炔基包括如前文定義之直鏈及分支鏈及環烷基 ,但兩 個碳原子間至少存在有一個參鍵。(C2_C8)炔基之實例包括 但非限於乙块、丙块、卜丁炔、2.丁块、1_戊炔、2_戊炔、 1-己炔、2-己炔、3_己炔、丨_庚炔、2_庚炔、3_庚炔、卜辛 炔、2-辛炔、3-辛炔及4_辛炔。炔基可未經取代或選擇性地 經以如後文說明之一個或多個取代基取代。 芳基為不含雜原子之環狀芳香族烴。芳基包括一環、 一%及多環環系。如此芳基包括但非限於苯基、奠基、聯 伸七苯基、聯伸苯基、節并苯基n菲基、聯伸三苯 21 201034690 基、祐基、萘并萘基、苯并菲基、聯笨基、蒽基、節基、 四氫節基、聯伸五苯基、及祕。於轩纽财,芳基 含有6至14财,於其它實施例中,該基之環部分含有6至 I2或甚至6至10個碳好。芳基包括經取代之絲經取代之 芳基。經取狀芳基可經-取代或經多於-次取代。舉例 言之,經-取代之芳基包括但非限於經2_、3_、4_、5_、或 6取代之苯基或基,其諸如前文列舉之取代基取 代。 芳院基為如前文定義之貌基其中烧基之氯或碳鍵係經 以鍵結至如前文定義之芳基之鍵置換。於若干實施例中, 芳烧基含有7至20個碳料、7至14個碳原子或7至職碳原 子。 雜環基包括含3«多個環成貢之料香環,其中一個 或多個環成員為雜原子諸如但非限於N、〇、及§。於若干 實施例中,雜環基包括3至2G個環成員,料它此等基團具 有3至6、3至1〇、3至12、或3至15個環成員。雜環基涵蓋不 飽和、部分飽和及飽和環系諸如咪唑基、咪唑啉基、及咪 唑啶基。雜環基可經取代或未經取代。雜環基包括但非限 於吖叽基、吖咀基、吡咯啶基、咪唑啶基、吡唑啶基、噻 唑啶基 '四氫噻吩基、四氫呋喃基、二噚呃基、呋喃基、 噻吩基、吡咯基、吡咯啉基、咪唑基、咪唑啉基、吡唑基、 吡唑啉基、三唑基、四唑基、噚唑基、異啰唑基噻唑基、 噻唑啉基、異噻唑基、噻二唑基、谔二唑基、哌啶基、哌 畊基、咮啉基、噻咮啉基、四氫哌喃基、四氫噻哌喃基、 22 201034690 噚噻σ山、二噚。山基、 塔11井基、娘_基、三啡基、 一虱二噻喃基、高派啡基、 一0塞β山基、°底喃基、°比咬基、喊咬基、 一氫。比。定基、二氫二喧。井基、 哏啶基、吲哚基、吲哚啉基、
異。《基、。丫啊基(鱗并㈣基)1絲、+巾基、苯 开三唾基、苯并料基、笨并料基、笨料吩基、笨并 嗟唾基、苯并$二唾基、苯并啊基、笨并二㈣基、笨 并啊啡基、苯并°㈣基、苯并十线、苯并射基、苯 、’ 坐基笨并[1,3] — 呢基、吼唾并。比咬基、咪唾并 比疋基(。丫苯并味唾基)、三唾并吼咬基、異十坐并吼咬基、 嗓吟基、料呤基、腺W基、鳥W基、顿基、異啥 琳基、十巾基、料似、七轉基"曾憾、吹啡基、 令唆基κ基、絲基Ί料料基、二氫苯并咬 喃基、二氫f朵基、二氫苯并二十井基'四氫十朵基、四
風°引唾基、四氫苯并咪唑基、四氫苯并三唑基、四氫吡咯 开吡啶基、四氫吡唑并吡啶基、四氫咪唑并吡啶基、四氫 坐并比疋基、及四虱啥琳基。雜環基可經取代或未經取 代。代表性經取代之雜環基可經一取代或經取代多於一 -人,諸如但非限於經2、3、4、5、或6取代或經以前文列舉 之多種取代基二取代之吡啶基或咮啉基。 雜芳基為含5個或更多個環成員之芳香環,其中一者或 多者為雜原子諸如但非限於N、0、及8。雜芳基可經取代 或未經取代。雜芳基包括但非限於下列基團諸如吡咯基、 吡唑基、三唑基、四唑基、哼唑基、異噚唑基、噻唑基、 比啶基、嗒啡基、嘧啶基、吡畊基、噻吩基、苯并噻吩基、 23 201034690 咬喃基、笨并料基、啊基、σ丫十朵基(料并吼咬基)、 叫卜坐基、笨并咪絲吟缉㈣基卜丫笨并料基卜比唾 并。比咬基、三唾并㈣基、笨并三絲、苯并十坐基、笨 并嗟唑基、笨并喧二唾基、味峻并吼咬基、異十坐并呢唆 基、養祕κ基、料呤基、腺嗓呤基、鳥嗓吟基、 苯并%唑基、苯并噚唑基、喹啉基、異喹啉基、四氯 喹啉基、喹噚啉基、及喹唑啉基。 烷氧基為其中鍵結至氫原子之鍵係經以經取代之或未 經取代之烷基諸如前文定義之碳原子之鍵置換之羥基 (-OH)。線性烷氧基之實例包括但非限於甲氧基、乙氧基、 丙氧基、丁氧基、戊氧基、己氧基等。分支烧氧基之實例 包括但非限於異丙氧基、第二丁氧基、第三丁氧基、異戊 氧基、異己氧基等。環烷氧基之實例包括但非限於環丙基 氧基、環丁基氧基、環戊基氧基、環己基氧基等。烷氧基 可經取代或未經取代。代表性經取代之烷氧基可經以諸如 前文列舉之取代基取代一次或多次。 「多環基」或「多環基團」等詞係指兩個或多個環(例 如環烷基類、環烯基類、環炔基類、芳基類及/或雜環基類) 其中兩個或多個碳為兩個鄰接環所共用,例如該等環為「稠 合環」。透過非相鄰原子接合之環定名為「橋接」環。多環 之各個環可經以前述該等取代基取代諸如鹵素、烷基、芳 烷基、烯基、炔基、環烷基、羥基、胺基、一烷基胺基、 二烷基胺基、硝基、毓基、亞胺基、醯胺基、膦酸基、亞 膦酸基、羰基、羧基、矽烷基、醚、烷硫基、磺醯基、酮、 24 201034690 越、酯、雜環基、芳香族或雜芳香族部分、_CF3、-CN等。 「碳環」一詞係指其中該環之各個原子為碳之芳香環 或非芳香環。 「硝基」一詞係指_N〇2 ;「鹵素」一詞為業界所已知且 係指-F、-Cl、_Br戒,「疏基」一詞為業界所已知且係指 -SH ;「羥基」〆詞表示;及「磺醢基」一詞為為業界 所已知且表示-S〇2。「鹵陰離子」表示鹵素之相對應陰離子 及「假_陰離子」具有C〇tton及Wilkinson所著「進階無機 化學」之560所陳述之定義。 「胺」或「戚基」等詞係指_NRCRd基其中R>Rd各自 分別表示氫、(CrCs)烷基 '芳基、雜芳基、及雜環烷基。 當Re及Rd係附接同一個氮原子時,其可與該氮原子組合 而形成5-、6-或7-員環。例如-NRCRd表示包括卜吡咯啶基、 吡啶基或4-咮啉基環。 「酿胺基」一詞為業界所瞭解之經胺基取代之幾基且 包括可以通式-C(0)NReRd基表示之部分,其中IHRd係如 前文定義。根據若干實施例,醯胺不包括可能不穩定之醯 亞胺類。 「羰基」及「羧酸根」等詞包括可以如下通式表示之 此等部分:
或
Rf 其中E為鍵結或表示〇或s,及Rf&Rf’分別為Η、烷基、烯基、 25 201034690 芳基、或藥學上可接受之鹽。當E為0及1^係如前文定義時, 該部分於此處稱作為羧基,且特別當R/為氫時該式表示「羧 酸」。一般而言,當明白顯示氧由硫所置換時,該式表示「硫 幾基」。 「烷氧基」或「烷氧」等詞係指具有氧基團附接其上 之如前文定義之烧基。代表性烧氧基包括甲氧基、乙氧基、 丙氧基、丁氧基、第三丁氧基等。「醚」為兩個烴藉一個氧 所共價鏈接。「醚」也涵蓋多醚,此處一個給定基中可存在 有多於一個醚基或鍵聯。「醚」也涵蓋環醚類及冠醚類,此 處醚鍵聯係於環狀基團内部。 「磺酸酯」一詞係指可由通式-S(0)2ORg表示之部分, 其中…為電子對、氫、烷基、環烷基、或芳基。「硫酸酯」 一詞包括可以通式表示之部分,其中Rg係如前文定義。「磺 醯胺」一詞包括可以通式:-N(Rf)S(0)20Rf’表示之部分, 其中Rf及Rf’係如前文定義。「硫醯胺」一詞係指可以通式 -S(0)2NReRf表示之部分,其中116及1^為氫、(CrC8)烷基或 芳基。「磺醯基」一詞係指可以通式:-S(0)2Rh表示之部分, 其中Rh為下列中之一者:氫、烷基、烯基、炔基、環烷基、 雜環基、芳基、或雜芳基。 各種表示法例如烷基、m、η等當其於任何結構式中出 現多於一次時其定義意圖與同一個結構式中它處之其定義 獨立無關。 三氟甲磺醯基、甲苯磺醯基、甲磺醯基、及九氟丁磺 醯基分別係指三氟甲烷磺醯基、對甲苯磺醯基、曱烷磺醯 26 201034690 基、及九氟丁烷磺醯基。三氟甲續酸酯、甲苯績酸酯、甲 石黃酸醋、及九氟丁續酸醋等詞為業界所已知且分別係指三 氟甲炫續酸酯、對曱苯石黃酸醋、甲燒續酸醋、及九氣丁燒 磺酸醋官能基及含有言亥等官能基之分子。縮寫Me、Et、ph、
Tf、Nf、Ts及Ms分別表示甲基、乙基、笨基、三氣甲石黃酿 基、九氟丁石黃醯基、對甲苯石黃酿基及甲續酿基。熟諸技藝 之有機化學師所利用的更綜合性縮寫表單出現於有機化學 〇 射彳各卷第U表單典型係以標準縮寫表單之表 格中呈現。 組成物所含之若干化合物可以特定幾何形式或立體異 構形式存在。此外,化合物也可為旋紐。化合物也可包 • 括順_及反_異構物m對映異構物、非對映異構物、⑼_ 異構物、(L)_異構物、其外消旋混合物、及其其它混合物。 額外非對稱碳原子可存在於取代基諸如烷基。例如若期望 化合物之特定對映異構物,則可藉非對稱合成或藉使用對 〇 掌輔劑衍生製備,此處結果所得之非對映異構混合物經分 離及輔基經裂解而提供純質期望的對映異構物。另外,當 分子含有鹼性官能基諸如胺基或酸性官能基諸如羧基時, 與適當旋光性酸或鹼形成非對映異構鹽,接著藉技藝界眾 所周知之分段結晶或層析術手段光學分割如此所形成之非 對映異構物’及隨後回收純質對映異構物。 如此處使用「保瘦基」一詞表不保護具有潛在反應性 之官能基免於出現非期望之化學轉換之暫時性取代基。此 等保護基之實例包括羧酸之酯、醇之石夕炫基醚、及醛及酮 27 201034690 分別之縮醛及縮酮。保護基化學領域已經綜論(Greene, T.W.; Wuts, P.G.M.,有機合成保護基,第三版;威利公司,紐約, 1999年)。 除非另行指示,否則「立體異構物」表示實質上不含 該化合物之其它立體異構物之一種化合物之立體異構物。 如此具有一個對掌中心之立體異構純質化合物將實質上不 含該化合物之相對對映異構物。具有兩個對掌中心之立體 異構純質化合物將實質上不含該化合物之其它非對映異構 物。典型立體異構純質化合物包含大於約80%重量比之該 化合物之一種立體異構物及小於約20%重量比之該化合物 之其它立體異構物,例如大於約90%重量比該化合物之一 種立體異構物及小於約10%重量比之該化合物之其它立體 異構物,或大於約95%重量比該化合物之一種立體異構物 及小於約5%重量比之該化合物之其它立體異構物,或大於 約97°/。重量比該化合物之一種立體異構物及小於約3%重量 比之該化合物之其它立體異構物。 若所示結構式與給予該結構式之命名間有歧異,則以 所示結構式為主。此外,若一個結構式或部分結構式之立 體化學未以粗體或虛線指示,則該結構式或該結構式部分 可解譯為涵蓋其全部立體異構物。 螯合化合物及其合成 於一個面相,提供式I化合物、其藥學上可接受之鹽、 及溶劑合物: 28 201034690 NRaRb 。丫0R 各
RO
此處,R為H、銨離子、烷基銨離子、鹼土金屬離子、稀土 金屬離子、或烷基;W為鍵結、-NHC(O)-、-CH(NH2)-、 -NH-C(O0-NH-、-C(0)-NH-、-C(0)-NH-CH(COOH)-、 -0-(CH2)n-0-(CH2)n- 、 -(CH2)nO(CH2)nO(CH2)n-、 O -CH(NHFmoc)- ; Z為鍵結、-CO(O)-、-NH-、-NHC(O)-、 -NH-C(0)-NH-、-NH-C(0)-(CH2)n-、-NH-C(0)-CH(NH2)-、 -C(0)-NH-CH(C00H)-;或-NH-C(0)-C6H4-(CH2)n-NH-; NRaRb為不存在或為下式螯合基:
29 201034690
Rt)OC
Rt〇ocr
RkDOQ
V
N N R'OOC ,或
Rt為H、CrC8烷基、銨離子 '烷基銨離子、或鹼金屬離子 或鹼土金屬離子;Rv為烷基;e為0至15之整數;f為0至15 之整數;g為0至15之整數;及η為0至10之整數;但限制條 件為若NRaRb為:
則當W為鍵結時,Ζ非為鍵結、-C(0)-NH-、或 -NHC(O)-;及當Z為鍵結時,W非為鍵結、-C(0)-NH-、或 -NHC(O)-。於若干實施例中,R為烷基。於其它實施例中, Rv為甲基、乙基、正丙基、異丙基、正丁基、異丁基、或 第三丁基。於又有其它實施例中,Rv為甲基。於又有其它 實施例中,各個β分別為Η或第三丁基。於又有其它實施例 中,R^H。 根據式I之實例化合物包括但非限於:
30 201034690
31 201034690
HO
32 201034690
co2h ο 又A H02C Ν Ν,、C02H Η Η 其藥學上可接受之鹽或溶劑合物;e為0至10之整數;f為0 至12之整數;g為0至12之整數;及η為0至10之整數。
根據多個實施例,該化合物之NRaRb基可進一步 螯合至金屬。於若干實施例中,金屬為放射性核種。 例如金屬可為鉻-99m或銖-186m/188m。錯合物諸如 [NEt4]2[MBr3(CO)3] ; Μ為Tc或Re可與式I化合物於醇系溶劑 反應而提供式Ι-M螯合化合物,容後詳述。
NRaRb—Μ 又·
Z
OR Ι-Μ 根據式I至式Μ之示例化合物包括但非限於下列中之任 ❹ 一者:
33 201034690
34 201034690
其藥學上可接受之鹽或溶劑合物;此處Μ為Re或Tc ; e為0 至10之整數;f為0至12之整數;g為0至12之整數;及η為Ο 至10之整數。 於若干實施例中,該等化合物不僅包括其藥學上可接 受之鹽及溶劑合物,同時也包括此等化合物之立體異構 物、互變異構物、及其前藥。 35 201034690 如前述,式i化合物可含有一個或多個放射性核種係適 合用作為放射性顯像劑及用於快速增殖細胞治療之療法。 如此,於一個實施例中,提供包括式I化合物、其鹽、溶劑 合物、立體異構物、或互變異構物及藥學上可接受之載劑 之藥學組成物。 大致上,式I化合物或其藥學組成物可經口投予或透過 腸道外途徑通常係藉注射投予。腸道外途徑包括但非限於 靜脈、肌肉、動脈内、鞘内、囊内、眶内、心内、皮内、 腹内、經氣管、皮下、角質層下、關節内、囊下、蜘蛛膜 下、椎骨内及胸骨内注射及輸注。於若干實施例中,該化 合物或其藥學組成物可經口投予。此等組成物可呈錠劑、 丸劑、膠囊劑、半固體、散劑、溶液劑、懸浮液劑、酿劑、 喷霧劑、或任何其它適當組成物劑型。 根據另一面相,提供適合用於活體内顯像之藥學組成 物。此等適當顯像藥學組成物含有足夠用於顯像之數量之 顯像劑,其具有呈元素亦即放射性碘或呈根據式〗化合物之 放射性金屬螯合物之放射性核種連同藥學上可接受之放射 學載媒劑。放射學載媒劑須適合用於注射或吸入,諸如人 血清白蛋白,水性緩衝液例如參(羥曱基)胺甲烷(及其鹽)、 磷酸鹽'檸檬酸鹽、碳酸氫鹽等;無菌水;生理食鹽1; 及含氣化物及/或二碳酸鹽及正常血漿陽離子諸如舞、钟、 納、及Μ之已平衡的離子性溶液。 於放射學載媒劑中之顯像劑濃度須足夠提供滿意的顯 像。例如當使用水溶液時,劑量約為1()至%毫居禮。顯像 36 201034690 劑須投予因而於病人體内維持約1小時至24小時,但更長及 更短的時間週期也可接受。因此可製備含有1毫升至10毫升 水溶液之方便的安瓿。
顯像可以標準方式進行,例如經由注射足量顯像組成 物來提供適當顯像及然後以適當機器諸如γ攝影機掃描。於 某些實施例中,一種顯像病人體之一區之方法包括下列步 驟:將診斷上有效量之化合物錯合放射性核種投予一病 人;將該病人之一區暴露於輻射;及獲得該病人該區影像。 於若干實施例中,顯像區為頭或胸。於其它實施例中,式I 化合物及錯合物係靶定PSMA蛋白質。 如此,於若干實施例中,提供一種顯像組織諸如脾組 織、腎組織、或PSMA-表現性腫瘤組織之方法,包括讓該 組織接觸包括放射性金屬及包括下式化合物:
其藥學上可接受之鹽或溶劑合物之錯合物。於若干實施例 中,該組織為PSMA表現性腫瘤組織。此等化合物之專一性 示例顯示於第5圖。 如此大致描述之本發明經由參考下列實例將更容易明 瞭,該等實例僅供舉例說明之用而絕非意圖限制本發明。 37 201034690 實例 概括合成方法 化合物與金屬錯合之概略程序。如此處舉例㈣,考 慮非放射性同位素之取得性及工作之安全性使用來 作為該金屬。但須瞭解也可使用鉻類似物遵照類似的合成 程序’原因在於錯及銖具有相似的反應化學且由於鋼系收 縮故具有相似的尺寸。因此可能特別顯示Re之處,須瞭解 也包括Tc錯合物。 用於銶錯合物形成之概略實驗條件 式I化合物之銖/錯錯合物可方便地自易得的前驅物 [NEt4]2[Re(CO)3Br3]與該化合物之反應中單離。由於SAAc 端末所提供之施體集合已經有明確文件記載為{M(CO)3} + 1 核心之有效螯合體’且已經設計來配合環繞金屬位置所需 的表面排列,錯合物的製備也不例外。 {Re(I)(CO)3}+系統遵循99mTc-三羰基核心反應化學 之相似的反應化學。使用[NEt4]2[ReBr3(CO)3]作為起始 物料結果導致有助於fac-{Re(CO)3(L)3}核心之形成。 [NEt4]2[ReBr3(CO)3]易衍生自[ReBr(CO)5]。Re(I)錯合物之 合成係經由[NEt4]2[ReBr3(CO)3]與適當螯合配體以1:1.2之 比例於10毫升甲醇反應達成。允許反應混合物於80°C加熱4 小時。冷卻後,全部反應產物皆使用C18賽派克(Sep Pak) 管柱純化,獲得20%至50%範圍之產率。 除非另行註明,Re(I)錯合物之合成係經由 [NEt4]2[ReBr3(CO)3](或[99mTc(CO)3(H2〇)3]+)與適當配體 38 201034690 (10·6Μ至10·4Μ)以1:1.2之比例於10毫升甲醇反應達成。密封 小瓶允許於100 °C加熱4小時。冷卻時,反應透過 RP-HPLC(反相HPLC)分析純度,產物係使用二氧化矽管柱 使用甲醇作為洗提劑純化。於HPLC純化後,獲得「無載劑」 產物之放射性化學純度(RCP)係透過HPLC測定,顯示為一 致地大於或等於95%。雖然初步結果驗證放射性標記濃度 低抵10_6M,RCY係小於或等於80%。RCY為放射性化學產 率的縮寫。為了於達成於75°C大於95%之RCY,反應濃度 須提高至10_4M。於多種情況下,相對應之tc錯合物係如同 Re錯合物製備及測試俾便製備用於測試目的及處置目的之 非放射性類似物。 化合物之放射性標記 式I化合物之放射性標記經完成來利用類似之方法於 自由態α-胺基酸上或呈經適當N_保護之胺基酸衍生物形成 錯合物。99mTc(I)(CO)3+放射性標記係使用市售埃索鏈 (IsoLink)套件組(可維汀公司(Covidien))以二步驟完成而形 成[99mTc(CO)3(H2〇)3]+)中間產物,其係於丨:丨之乙腈及磷酸 鹽緩衝液的等體積混合物中,與適當式〗化合物(1〇-6M至 10_4M)反應。密封小瓶於100〇c加熱3〇分鐘。冷卻時,透過 RP-HPLC分析純度。HPLC純化後獲得「無載劑」產物之放 射性化學純度(RCP)係透過HPLC測定’顯示為一致地大於 或等於95%。雖然初步結果證實於低抵1〇-6M濃度之放射性 標圮,RCY係小於或等於8〇%。為了達成於75。〇大於95%之 RCY,反應濃度須提高至1〇-4M ^於多種情況下,相對應尺6 39 201034690 錯合物係如抓錯合物般製備及 的及處置目的之非放射性I便1備用於測試目 須瞭解也含括Te錯合物。 因此當特別顯示Re時, 實例式I化合物之合成 反應圖1為基於Glu-尿素啐人仏 c ^ 京+唑化合物之概略合成途徑 :說明圖。反應圖1所示第-步驟係使用麵胺酸與⑽之二 弟三丁醋於驗存訂,於舰條件下於叱進行而形成中間 產物伽尿素味嗤衍生物2。此中間產物於驗性條件下以 Me嶋化獲得甲基化咪唾,其於惰性條件下易與胺反 應。第二丁酯保護基係使用20% TFAkDCM於室溫歷經工 J時至4小時移除。脫去保護完成時,反應混合物於旋轉蒸 發器上濃縮或以氮氣吹乾及於二氧化矽管柱上純化或再結 晶。 反應圖1 .0.
Y^NH”HC 丨
DCM
CDI, TEA
Ο
通式結構式E化合物係使用反應圖2所示概略程序,以 100/。至50%範圍之總產率製備。關鍵合成中間產物係經由適 201034690
當搭於至溫反應1小時形成中間產物席夫驗(Schiff base)而 形成。席夫鹼未經單離,反而使用三乙醯氧硼氫化鈉於原 位還原而形成貳-衍生之胺(B)。衍生之胺使用端末羧酸、 HATU (2-(1Η-7-吖苯并三唑小基四曱基脲鐯六氟 磷酸甲銨)及鹼偶合至2-[3-(5·胺-1-第三丁氧羰基-戊基)-脲]-戊二酸二第三丁酯(A)而形成經保護之中間產物C。Re(I) 錯合物(D)之合成係經由[NEt4]2[ReBr3(CO)3]與適當配體以 1:1.2之比於10毫升甲醇反應達成。允許反應於80°c加熱4 小時。冷卻後,全部下列反應產物皆使用C18埃索鏈管柱純 化,產率係於20%至50%之範圍。
反應圖2. M-Glu-尿素_Lys-X類似物(E)之概略合成途徑
第三丁酯保護基係使用50% TFA於DCM於室溫歷經12 小時時間移除。脫保護完成時,反應係於旋轉蒸發器上濃 縮及藉HPLC或急速層析術純化,獲得期望產物(E),產率 201034690 10% 至 50%。 實例 1 : [Re(CO)3{(S)-2-(3-((R)-5-(貳((1-(羧甲基)-1Η-13米。坐-2-基)甲基)胺)-1-竣戊基)脲)戍二酸}]
(S)-2-(3-((R)-5-(貳((1-(羧甲基)-1Η-咪唑-2-基)甲基)胺)小 羧戊基)脲)戊二酸係採用反應圖1所示之相同概略程序,使 用2-[3-(5-胺-1-羧戊基)-脲]-戊二酸二第三丁酯製備。銶酯 錯合物係採用如概略銖實驗中所述之相同程序製備。化合 物係使用前述方法採用TFA脫去保護,獲得期望產物(4.0毫 克,29%)呈灰白色固體。1H NMR (400 MHz, DMSO-d6) δ 7.2 (s, 2Η), 7.0 (s, 2H), 6.3 (s, 2H), 4.85 (s, 4H), 4.55 (d, 2H), 4.4 (d, 2H), 4.10 (s, 2H), 3.5 (s, 2H), 2.2 (m, 2H), 1.7 (m, 6H), 1.25 (m, 2H). ESMS m/z: 866 (M+H)+。 實例2 : [Re(CO)3{(14R,18S)-l-(l-(羧甲基)-1Η-咪唑-2-基)-2-((1-(羧甲基)-1Η-咪唑-2-基)曱基)-8,16-二酮 -2,9,15,17-四吖廿烷-14,18,20-三羧酸}]
42 201034690
備。銖酯錯合物係採用如概略鍊實驗中所述之相 同程序製 備。化合物係使用前述方法採用TFA脫去保護,獲得期望 產物(8.0毫克’ 13。/〇)呈灰白色固體。iH NMR (4〇〇 MHz, DMSO-d6) δ 7.9 (s, Η), 7.2 (s, 2Η), 7.0 (2, 2Η), 6.3 (s, 2H), 4.85 (s, 4H), 4.55 (d, 2H), 4.4 (d, 2H), 4.1 (m, 2H), 3.5 (s, 2H), 2.9 (s, 4H), 2.2 (m, 2H), 2.05 (m, 2H), 1.85 (m, 2H), 1.6 (m, 6H),1.3 (m,4H). ESMS m/z: 979 (M+H)+。 實例3 : [Re(CO)3{(19R,23S)-l-(l-(羧曱基)-lH-咪唑-2-基)-2-((1-(羧甲基)-1Η-咪唑-2-基)甲基)-13,21-二酮 -2,14,20,22-四吖廿五烷-19,23,25-三羧酸}]
(19R,23S)-l-(l-(羧甲基)-1Η-咪唑-2-基)-2-((1-(羧曱基)-iH-咪唑-2-基)曱基)-13,21-二酮-2,14,20,22-四吖廿五烷 -19,23,25-三羧酸係採用反應圖1所示之相同概略程序,使用 先前已製備且經保護之2-[3-(5-胺-1-羧戊基)-脲]-戊二酸二 43 201034690 第三丁酯製備。銖酯錯合物係採用如概略銖實驗中所述之 相同程序製備。化合物係使用前述方法採用TFA脫去保 護,獲得期望產物(7.0毫克,24%)呈灰白色固體。1HNMR (400 MHz, DMSO-d6) δ 7.8 (s, Η), 7.2 (s, 2H), 7.0 (2, 2H), 6.3 (s, 2H), 4.8 (s, 4H), 4.55 (d, 2H), 4.4 (d, 2H), 4.1 (m, 2H), 3.5 (m, 2H), 2.9 (m, 2H), 2.2 (m, 2H), 2.05 (m, 4H), 1.9 (m, 4H), 1.6 (m, 4H), 1.4 (m, 2H) 1.3 (m, 16H). ESMS m/z\ 525 (M/2). 實例4 : [Re(CO)3{(17R,21S)-l-(l-(羧曱基)-lH-咪唑-2-基)-2-((1-(羧甲基)-1Η-咪唑-2-基)曱基)-11,19-二酮-5,8-二 口号-2,12,18,20-四吖廿三烷-17,21,23-三羧酸}]
(17R,21S)-l-(l-(羧甲基)-1Η-咪唑-2-基)-2-((1-(羧甲基)-1Η-咪唑-2-基)甲基)-11,19-二酮-5,8-二噚-2,12,18,20-四吖廿三 烷-17,21,23-三羧酸係採用反應圖1所示之相同概略程序,使 用先前已製備且經保護之2-[3-(5-胺-1-羧戊基)-脲]-戊二酸 二第三丁酯製備。銖酯錯合物係採用如概略銖實驗中所述 之相同程序製備。化合物係使用前述方法採用TFA脫去保 護,獲得期望產物(6.0毫克,38%)呈灰白色固體。1H NMR 44 201034690 (400 MHz, DMSO-d6) δ 7.9 (s, Η), 7.2 (s, 2Η), 7.0 (s, 2H), 6.3 (s, 2H), 4.85 (s, 4H), 4.6 (d, 2H), 4.5 (d, 2H), 3.80 (m, 12H), 3_5 (m,10H), 2.4 (m, 4H). ESMS w/z: 738 (M+H)+。 實例5 :
❹ ❹ 實例 5a (n=2) : Glu-尿素-Lys-PEG2-ReDP : [Re(CO)3 {(17R,21S)-11,19·二 _ (吡啶 _2_ 基)_2_(吡啶 _2_ 基甲 基)-5,8- — 亏2,12,18,2〇_四吖廿三烷_17 21 23_三羧 酉夂}][Br]。 基曱基)-5,8-二Df-2,1218,四β丫廿三烧·17 21,23三敌酸 係採用反應圖1所示之相同概略程序,使贱前已製備且經 保護之2·[3·(5·胺],戊基)_脲]_戊二酸二第三丁醋製備。 #8曰錯如概略銖實驗巾所述之相同程序製備。 化口物係使用則述方法採用權脫去㈣,獲得期望產物(2 毫克 2〇/〇)呈灰白色固體。1H NMR (4〇〇 MHz, DMSO-i/6) δ 8.8 (d), 8.00 (dd) 7 , Λ 7·55 (d), 7.42 (dd), 6.45 (s), 3.95 (m), 3.4-3.6 (m), 2.45 (m\ Λ V ^ 1-25 (m), 1.1 (m), 0.8 (m). ESMS m/z: 45 201034690 931 (M+H)+ ° 實例 5b (11=4) : Glu-尿素 _Lys-PEG4-ReDP : [Re(CO)3 {(23R,27S)-17,25-二酮-1-(吡啶-2-基)-2-(吡啶-2-基甲 基)-5,8,11,14-四噚-2,18,24,26-四吖廿九烷-23,27,29-三羧 酸}]旧1·]。(23R,27S)-17,25-二酮小^比咬^基)_2_(口比〇定_2_ 基甲基)-5,8,11,14-四呤-2,18,24,26-四吖廿九烷-23,27,29-三 羧酸係採用實例6a之相同概略程序製備,使用先前已製備 且經保護之2-[3-(5-胺-1-緩戊基)-脲]-戊二酸二第三丁酯製 備。銖酯錯合物係採用如概略銖實驗中所述之相同程序製 備。化合物係使用前述方法採用TFA脫去保護,獲得期望 產物(5.1毫克,29.6%)呈白色固體。ESMS w/z: 1019 (M+H)+。 實例 5c (n=8) : Glu-尿素-Lys-PEG8-ReDP : [Re(c〇)3 {(35R,39S)-29,37-二酮-1-( °比。定-2-基)-2-( 0比咬 _2基曱 基)-5,8,11,14,17,20,23,26-八哼-2,30,36,38-四。丫 廿四烧 _35,39,41_三叛酸}][Br]。PEG8二D比唆基化合物, (35R,39S)-29,37-二酮-1-(吡啶-2-基)-2-(吡啶 _2_ 基甲 S)-5,8,ll,14,17,20,23,26~Y^-2,30,36,38-ra4*w^ -35,39,41-三羧酸係採用實例6a之相同概略程序製備,使用 先前已製備且經保護之2-[3-(5-胺-1-羧戊基)-脲]•戊二酸二 第二丁酯製備。銖酯錯合物係採用如概略銖實驗中所述之 相同程序製備。化合物係使用前述方法採用TFA脫去保 護’獲得期望產物(8.0毫克,30.4%)呈白色固體。ESMS w/z: 1195 (M+H)+ 〇 46 201034690 實例6 : [Re(CO)3][(19R,23S)-l-(l-(羧甲基)-1Η—味嗤_2-基)-2_((1-(羧甲基)-1Η-咪唑-2-基)甲基)-13,21·二酮 -2,14,20,22-四吖廿五烷-1,19,23,25-四羧酸]
步驟1. 11-(〇第三丁氧_2_酮乙基)((丨_(2-第三丁氧_2_ 酮乙基H1H-咪唑-2-基)_甲基)胺)十一烷酸: 0^/0、
11_胺十—烷酸(603毫克,3·〇毫莫耳),2_吡啶羧醛(630毫 克’ 3·0毫莫耳)及乙酸(〇_20毫升)於DCE(20毫升)之懸浮液於 氮下回流30分鐘。反應混合物冷卻至〇 π,及循序以 NaBH(OAc)3 (1.9〇8克,9〇毫莫耳)及粗產物乙搭酸第三丁 醋(1.50克,11.5毫莫耳)處理。反應混合物於室溫授掉隔夜 =水反應混合物以職萃取。有機層經脫水及於 化獲得晴柱純 基Η㈣-基”基)胺)十一寒3毫;=黃乙 47 201034690 色油。NMR (400 MHz, CDC13) 7.01 (d,J= 1.2 Hz,0.46 H), 6.99 (d, J= 12 Hz, 0.54 H), 6.88 (d, y = 1.2 Hz, 0.54 H), 6.86 (d, J = 1.2 Hz, 0.46 H), 5.30 (s, 1.08 H), 5.07 (s, 0.92 H), 4.67 (s, 2 H), 4.66 (s, 2 H), 3.83 (s, 0.92 H), 3.17 (s, 1.08 H), 2.41-2.32 (m, 2 H), 1.66-1.63 (m, 2 H), 1.47 (s, 9 H), 1.45 (s,9 H),1.42-1.10 (m, 14 H); MS (ESI), 510 (M+H)+。 步驟2· (19S,23S)-2-((l-(2-第三丁氧-2-酮乙基)-lH-咪 唑-2-基)-甲基)-13,21-二酮-2,14,20,22-四吖廿五烷 -1,19,23,25-四羧酸四-第三丁酯:
(S)-2_(3-((S)-6-胺-1-第三丁氧·ι_酮己_2_基)腺)戊二酸二第 三丁酯(85毫克,0.175毫莫耳),第三丁氧_2_酮乙 基)((1-(2-第三丁氧-2-酮乙基)_(ιη-咪唑-2-基)-甲基)胺)十 一烷酸(89毫克,0.175毫莫耳),EDCI(1-乙基-3-(3-二曱基 胺丙基)甲二醯亞胺)(38毫克,〇·2〇毫莫耳),HOBt (1-羥苯 并三唑)(26毫克,〇.2〇毫莫耳^DIpEA (〇3〇毫升)於 DCM(5_0毫升)之溶液於室溫攪拌3日。反應混合物藉拜堤純 化,以1%至1〇〇/0曱醇於二氣甲烷洗提獲得(19S,23s)_2_ ((1-(2-第二丁氧-2-酮乙基)_1H_咪唑_2_基)_ 甲基)_13,21_二 48 201034690 酮-2,14,20,22-四吖廿五烷_1,19,23,25-四羧酸四-第三丁酯 (111毫克,65%)呈黃色油。MS(ESI),490.5 (M/2+H)+。 步驟3. [Re(CO)3][(19R,23S)-l-(l-(羧甲基)-1Η-咪唑-2-基)-2-((1-(羧甲基)_1H-咪唑-2-基)甲基)-13,21-二酮 -2,14,20,22-四吖廿五烷-1,19,23,25-四羧酸](221)。 (19S,23S)-2_((l-(2-第三丁氧-2-酮乙基)-1Η-咪唑-2-基)-曱 基)-13,21-二酮-2,14,20,22-四吖廿五烷-1,19,23,25-四羧酸 四-第三丁酯(18.8毫克,〇·〇19毫莫耳)於TFA(1.0毫 升)/DCM(1.0毫升)之溶液於室溫攪拌隔夜。溶劑經蒸發獲 得(19R,23S)-l-(l-(羧甲基)_1H-咪唑-2-基)-2-((1-(羧甲 基)-1Η-咪唑-2-基)曱基)-13,21-二酮-2,14,20,22-四吖廿五烷 -1,19,23,25-四羧酸呈無色油。於前述以脫保護之產物於水 (1 _0毫升)且藉2N氫氧化鈉調整至pH為9之溶液内添加 Re(CO)3(H2O)OTf(0.50毫升,〇.1〇毫升/毫莫耳)。反應混合 物於室溫攪拌隔夜及藉HPLC純化獲得標題化合物(4.0毫 克 ’ 19%)呈白色固體。4 NMR (400 MHz, DMSO〇 7.70 (t, J= 5.6 Hz, 1 Η), 7.33 (s, 1 Η), 7.13 (s, 2 Η), 6.29 (d, J= 8.4 Hz, 1 H), 6.26 (d, J= 8.4 Hz, 1 H), 4.96 (d, J= 4.8 Hz, 2 H), 4.56 (d, J = 16.4 Hz, 1 H), 4.12 (d, J = 16.8 Hz, 1 H), 4.07-3.90 (m, 2 H), 3.70 (d, J = 17.2 Hz, 1 H), 3.40 (d, J = 17.2 Hz, 1 H), 2.98-2.94 (m, 4 H), 2.21 (q, J= 7.73, 2 H), 1.99 (t, /= 7.6 Hz, 2 H), 1.70-1.22 (m, 24 H); MS (ESI), 485_2 (M/2+H)+。 實例7: [Re(CO)3][(7S,14S,18S)-7-胺-1-(1-(羧甲基)-lH- 49 201034690 咪唑-2-基)-2-((1-(羧曱基)-1Η-咪唑-2-基)曱基)-8,16-二酮 -2,9,15,17-四吖廿烷-14,18,20-三羧酸]
Re(CO)3 步驟 1. (5S,12S,16S)-5-(4-(貳((1-(2-第三丁氧-2-酮乙 基)-111-咪唑-2-基)甲基)胺)丁基)-1-(911-苟-9-基)-3,6,14-三 酮-2-噚-4,7,13,15-四吖十八烷-12,16,18-三羧酸三-第三丁酯
(S)-2-(3-((S)-6-胺-1-第三丁氧-1-酮己-2-基)脲)戊二酸二第 三丁酯(97毫克,0.20毫莫耳),化合物2 (Ml毫克,0.2〇毫 莫耳),EDCI (38毫克,0.20毫莫耳),HOBt (26毫克,0.20 毫莫耳)及DIPEA(0.30毫升)於DCM(5.0毫升)之溶液於室溫 攪拌隔夜。反應混合物藉拜堤純化,以1%至10%甲醇於 DCM洗提獲得(5S,12S,16S)-5-(4-(貳((1-(2-第三丁氧-2-酮 50 201034690 乙基)-1Η-咪唑-2-基)曱基)胺)丁基)-1-(9Η-^-9-基)-3,6,14-三酮-2-噚-4,7,13,15-四吖十八烷-12,16,18-三羧酸三-第三 丁酯(85.7毫克,35%)呈白色固體。4 NMR (400 MHz, CDC13) 7.75 (d, J = 7.6 Hz, 2 H), 7.64 (d, J = 7.6 Hz, 2 H), 7.38 (t,J= 7.4 Hz, 2 H), 7.29 (dd, J= 7.6, 4.4 Hz, 2 H), 7.02 (brs, 1 H), 6.93 (s, 2 H), 6.80 (s, 2 H), 6.08 (d, J = 8.0 Hz, 1 H), 5.75 (d, J = 8.8 Hz, 1 H), 5.67 (d, J = 7.6 Hz, 1 H), 4.58 (s, 2 H), 4.56 (s, 2 H), 4.55-4.52 (m, 1 H), 4.36-4.29 (m, 3 H), 〇 v 4.21 (d, / = 7.0 Hz, 1 H), 4.13 (t, /= 6.8 Hz, 1 H), 3.63 (s, 4 H), 3.48-3.46 (m, 1 H), 3.05-3.01 (m, 1 H), 2.53 (t, 7.2
Hz, 2 H), 2.33-2.26 (m, 2 H), 2.07-2.00 (m, 2 H), 1.77-1.26 (m,55 H); MS (ESI),614.0 (M/2+H)+。 步驟 2· (7S,14S,18S)-7-胺-1-(1-(2-第三丁氧-2-酮乙 • 基)-1Η-咪唑-2-基)-2-((1-(2-第三丁氧-2-酮乙基)-1Η-咪唑 -2-基)甲基)-8,16-二明-2,9,15,17-四 σ丫廿烧-14,18,20-三叛酸 三-第三丁酯 〇
51 201034690 〇坐_2_基)甲基)胺)丁基)-1-(9Η-芴-9-基)-3,6,14-三酮 _2·噚-4,7,13,15-四吖十八烷_12,16,18_三羧酸三_第三丁酯 (84毫克’ 0.069毫莫耳)於DMF(〇 5〇毫升)之溶液内添加哌啶 (0.50毫升)。混合物於室溫攪拌2小時。於減壓下蒸發去除 溶劑獲得殘餘物,殘餘物藉拜堤以5%至25%甲醇於1)(:]^洗 提純化獲得(7S,14S,18S)-7·胺-1-(1-(2-第三丁氧_2_酮乙 基)-1H-咪唑-2-基)_2-((丨_(2_第三丁氧_2-酮乙基)-1H-咪唑 -2-基)甲基)-8,16-二酮_2,9,15,17-四 η丫廿炫-14,18,20-三羧酸 二-第三丁酉旨(59毫克,86%)。iHNMR (4〇〇 mHz,,CDC13) 6.96 (d, 0.8 Hz, 2 H), 6.85 (d, J = 0.8 Hz, 2 H), 5.55 (brs, 1 H), 5.43 (brs, 1 H), 4.59 (s, 4 H), 4.37-4.28 (m, 2 H), 3.61 (s, 4 H), 3.35-3.27 (m, 2 H), 3.18-3.12 (m, 1 H), 2.53 (t, J = 7.4 Hz, 2 H), 2.34-2.28 (m, 2 H), 2.10-2.00 (m, 2 H), 1.85-1.26 (m, 55 H); MS (ESI), 503.0 (M/2+H)+ ° 步驟3. [Re(c〇)3][(7S,14S,18S)-7-胺-1-(1-(羧甲基)·1Η- 咪唑-2-基)-2-(( 1 -(羧曱基)-1H-咪唑-2-基)甲基)_8,16_二酮 -2,9,15,17_四吖廿烷_14,18,20-三羧酸]。(78,148,188)-7-胺 -1-(1-(2-第三丁氧_2_酮乙基)-1Η-咪唑-2-基)-2-((1-(2-第三 丁氧-2-酮乙基)_iH-咪唑-2-基)甲基)-8,16-二酮 _2,9,15,17-四吖廿烷-14,18,20-三羧酸三-第三丁酯(42毫克,0·042毫莫 耳)及[NEt4]2[Re(c〇)3Br3](42毫克,0.055毫莫耳)於甲醇(5 毫升)之溶液於加壓管内於90〇c攪拌4小時。溶劑經蒸發去 除獲得殘餘物,殘餘物直接用於次一步驟。前述產物於 TFA(3.〇毫升)/DCM(3 〇毫升)之溶液於室溫攪拌隔夜。蒸發 52 201034690 去除溶劑獲得粗產物,藉HPLC純化獲得標題化合物(27.9 毫克,67%經2步驟)呈白色固體。4 NMR (400 MHz, DMSO-^) 8.42 (brs, 1 Η), 8.10 (brs, 2 Η), 7.18 (s, 2 Η), 7.04 (s, 2 Η), 6.32 (d, J= 8.4 Hz, 1 H), 6.29 (d, J= 8.0 Hz, 1 H), 4.02 (s, 4 H), 4.56-4.37 (m, 4 H), 4.08-4.01 (m, 2 H), 3.68-3.61 (m, 3 H), 3.11-3.08 (m, 2 H), 2.23-1.29 (m, 16 H); MS (ESI), 497.7 (M/2+H)+。 Ο 實例8 : [Re(CO)3][(19S,23S)-l-(l-(2-(底(羧甲基)胺)_2-酮乙基)-1Η-咪唑-2-基)-2-((1-(2-(貳(羧曱基)胺)_2_酮乙 基)-1Η-η米峻-2-基)甲基)-13,21-二酮-2,14,20,22-四n丫廿五烧 -19,23,25-三羧酸]。
〇 步驟1.2,2’-(2-溴乙醯基氮烷二基)二乙酸第三丁酿。於 2,2’-氮烷二基二乙酸第三丁酯(3〇〇克,ι2 24毫莫耳)及2_ >臭乙酿漠(1.39毫升,3.23克’ 16.00毫莫耳)於〇〇厘(100毫升) 之溶液内於室溫添加三乙基胺(2_〇毫升)。反應混合物於室 溫攪拌2小時。反應混合物以DCM(300毫升)稀釋,以水洗 滌及以硫酸鈉脫水。於減壓下蒸發去除溶劑獲得殘餘物, 53 201034690
藉拜堤純化,以10%己烷類於乙酸乙酯至50%己烷類於乙酸 乙酯洗提獲得2,2’-(2-溴乙醯基氮烷二基)二乙酸第三丁酯 (4.68克,100%)。1HNMR(400 MHz,CDCl3)4.09(s,2H), 4.07 (s,2 H), 3.86 (s, 2 H), 1.49 (s,9 H),1.46 (s,9 H); MS (ESI),388, 390 (M+Na)+。 步驟2· 2,2’-(2-(2-甲醯基-1H-咪唑-1-基)乙醯基氮烷二 基)二乙酸第三丁酯
2,2-(2->臭乙酿基亂烧二基)二乙酸第三丁醋(4·55克,12.43 毫莫耳)’ 1Η-味唑-2-甲醛(1.536克,16_0毫莫耳),DIPEA(5 〇 毫升)及KI(0.64克,4.0毫莫耳)之溶液於肋它攪拌隔夜。於 減壓下蒸發去除溶劑後,反應混合物以DCM稀釋,b 滌及乾燥。於減壓下蒸發去除溶劑獲得殘餘物,殘餘物“ 拜堤純化以DCM至3〇/〇曱醇於DCM洗提獲得2,2,-(2七、藉 基-1Η-咪唑-1-基)乙醯基氮烷二基)二乙酸第二 .〇 , 矛—丁暍α% 克,84%)。H NMR (400 MHz, CDC13) 9.76 (s 1 Η、<7 ’ h 7-3l (s 1 H),7.25 (s, 1 Η), 5.30 (s, 2 Η), 4.14 (s,2 Η), 4.07 (s 2 ,
Ul (s, 9 H), 1.43 (s, 9 H); MS (ESI), 382 (M+H)+。 H)’ 步驟3. 11-(家((l-(2_(紙(2_第三丁氧_2_酮乙基)胺 乙基)-1Η-咪唑_2_基)甲基)胺)十一烷酸 綱 54 201034690
11-胺十一烷酸(1〇〇毫克,〇_5〇毫莫耳),2,2,_(2-(2-曱醯基
_1H_咪唾·1-基)乙醯基氮烷二基)二乙酸第三丁酯(381毫 克’ 1.0¾莫耳)及乙酸(0_02毫升)於dce(30毫升)之溶液於氮 下於75 °C攪拌30分鐘。反應混合物冷卻炱0 °C及以 NaBH(OAc)3 (0.3165克,1.5毫莫耳)處理。反應混合物於室 溫授拌隔夜及以水分解。於減壓下蒸發去除溶劑獲得殘餘 物,殘餘物藉拜堤純化以1%至1〇%甲醇於DCM洗提獲得 11-(貳((1-(2-(貳(2-第三丁氧-2-酮乙基)胺)-2-酮乙基)-lH-咪。坐-2-基)甲基)胺)十一烷酸(368毫克,79%)。4 NMR (400 MHz, DMSO-J6) 6.93 (s, 2 Η), 6.76 (s, 2 Η), 5.02 (s, 4 Η), 4.29 (s, 4 Η), 3.93 (s, 4 Η), 3.44 (s, 4 Η), 2.30 (t,J=7.6 Hz, 2 Η), 2.09 (t, 7.6 Hz, 2 H), 1.43 (s, 18 H), 1.35 (s, 18 H), 1.29-1.00 (m, 16 H); MS (ESI), 466.9 (M/2+H)+ 〇 步驟4· (19S,23S)-l-(l-(2-(貳(2-第三丁氧_2·酮乙基) 胺)-2-酮乙基)-1Η-咪唑-2-基)-2-((1-(2-(貳(2-第三丁氧-2-酮 乙基)胺)-2-酮乙基)-1Η-咪唑-2-基)甲基)-13,21-二酮 -2,14,20,22_四吖廿五烷-19,23,25-三羧酸三_第三丁酯 55
X 201034690 ο
(S)-2-(3-((S)-6-胺-1-第三丁氧-1-酮己-2-基)脲)戊二酸二-第 三丁酯(85毫克,0.174毫莫耳),11-(貳((1-(2-(貳(2-第三丁 氧-2-酮乙基)胺)-2-酮乙基)-1Η-咪唑-2-基)曱基)胺)十一烷 酸(118毫克,0.127毫莫耳),EDCI(38毫克,0.20毫莫耳), HOBt(26毫克,0.20毫莫耳)及DIPEA(0.30毫升)於DCM(5.0 毫升)之溶液於室溫攪拌隔夜。反應混合物藉拜堤以1%至 10%甲醇於DCM洗提純化獲得(19S,23S)-l-(l-(2-(貳(2-第三 丁氧-2-嗣乙基)胺)-2-嗣乙基)-1H- 0米。坐-2 -基)-2-((1-(2-(武 (2-第三丁氧-2-酮乙基)胺)-2-酮乙基)-1Η-咪唑-2-基)甲 基)-13,21-二酮-2,14,20,22-四吖廿五烷-19,23,25-三羧酸三-第三丁酯(38毫克,21%)呈無色油。1H NMR (400 MHz, CDC13) 6.95 (d, J= 1.2 Hz, 2 H), 6.83 (d, J = 0.80 Hz, 2 H), 5.97 (s, 1 H), 5.28 (d, /= 7.6 Hz, 1 H), 5.23 (d, 8.4 Hz, 1 H), 4.94 (s, 4 H), 4.33-4.25 (m, 2 H), 4.12 (s, 4 H), 4.03 (s, 4 H), 3.63 (s, 4 H), 3.25-3.16 (m, 2 H), 2.53 (t, J= 7.4 Hz, 2 H), 2.33-2.24 (m, 2 H), 2.15 (t, J = 7.6 Hz, 2 H), 2.08-2.03 56 201034690 (m,2 Η), 2.02-1.20 (m,85 H); MS (ESI), 701.6 (M/2+H)+。 步驟5. [Re(CO)3][(19S,23S)-l-(l-(2-(貳(羧甲基)胺)_2_ 酮乙基)-1Η-咪唑-2-基)-2-((1-(2-(貳(羧甲基)胺)-2-酮乙 基)-1Η-咪唑-2-基)曱基)-13,21-二酮-2,14,20,22-四吖廿五烷 -19,23,25-三羧酸](223)。(195,238)-1-(1-(2-(貳(2-第三丁氧 -2-酮乙基)胺)-2-酮乙基)-1Η-咪。坐-2-基)-2-((1-(2-(貳(2-第 二丁氧-2-¾乙基)胺)-2-_乙基)-1Η-咪峻-2-基)甲基)-13,21- 一嗣_2,14,20,22_四0丫廿五炫>-19,23,25-三叛酸三-第三丁 @旨 (28宅克,0.02宅莫耳)及[NEt;4]2[Re(CO)3 Br3](30毫克,0.039 毫莫耳)於曱醇(5毫升)之溶液於加壓管内於9〇。〇攪拌隔 仪。条發去除溶劑獲得殘餘物,殘餘物直接用於次一步驟。 月ij述產物於TFA (3.0¾升)/DCM(3.0毫升)之溶液於室溫攪 拌3小時。条發去除溶劑獲得粗產物,粗產物藉純化, 獲得標題化合物(17.6毫克,69%經2步驟)呈白色固體。ιΗ NMR (400 MHz, OMSO-d6) 1JQ (t, 4.8 Hz, 1 H), 7.10 (s5 2 H), 7.03 (s, 2 H), 6.29 (d, /= 8.4 Hz, 1 H), 6.26 (d, J = 8.4
Hz, 1 H), 5.02 (s, 4 H), 4.37-3.97 (m, 14 H), 3.60-3.57 (m, 2 H), 3.01-2.94 (m, 2 H), 2.24-1.22 (m, 28 H); MS (ESI), 640.3 (M/2+H)+。 實例9 · [ReCCO^AUS’lSSp-HK2·(武(叛甲 基)胺)-2-酮乙基HHH2_基)_2_((1_(2侦叛曱基赃I 鲷乙基)_1H-咪嗤·2·基)甲基)_8,16_二__2,9,15,17四σ丫廿烧 -14,18,20-三叛酸] 57 201034690
步驟1. 2-(((9HU-基)甲氧)幾基胺)-6-(貳(ο#·(武 (2-第三丁氧-2-酮乙基)胺)_2_酮乙基)-1Η-咪唑-2-基)曱基) 胺)己酸。
L-Fmoc-離胺酸-〇Η(0·202克,0.50毫莫耳),2,2,-(2_(2·曱醯 基-1Η-咪唑-1-基)乙醢基氮烷二基)二乙酸第三丁酯(0 381 克,1.00毫莫耳)於DCE(30毫升)之懸浮液於80t加熱30分 鐘。反應混合物冷卻至〇。〇及以NaBH(〇 Ac)3 (0.3165克,1.50 毫莫耳)處理。反應於室溫攪拌丨2小時及以水分解。反應混 合物以DCM萃取。有機層經乾燥及於減壓下濃縮。殘餘物 藉拜堤SP4以5%至25%甲醇於DCM之梯度方法純化獲得 2_(((9H_芴_9-基)甲氧)羰基胺)-6-(貳((1-(2-(貳(2-第三丁氧 -2-剩乙基)胺)_2_酮乙基)_m_咪唑_2基)甲基)胺)己酸呈白 色固體(0.408克,74%產率)。'H NMR (400 MHz,CDCi3) 58 201034690 7.74 (d, J = 7.6 Hz, 2 H), 7.67 (t, J = 6.0 Hz, 2 H), 7.38 (i, J =7.4 Hz, 2 H), 7.29 (d, / = 7.6 Hz, 2 H), 6.92 (s, 2 H), 6.29 (s, 2 H), 6.19 (brs, 1 H), 5.09-5.04 (m, 2 H), 4.81-4.79 (m, 1 H), 4.39-4.30 (m, 4 H), 4.23 (t, J= 7.2 Hz, 1 H), 4.22-3.58 (m, 10 H), 3.48 (s, 2 H), 2.34-2.30 (m, 2 H), 1.67-1.26 (m, 6 H), 1.50 (s, 18 H), 1.42 (s, 18 H). ESMS m/z: 550.5 (M/2+H)+。
步驟2. (7S,14S,18S)-7-胺-1-(1-(2-(貳(2-第三丁氧-2-酮 乙基)胺)-2-酮乙基)-1Η-咪唑-2-基)-2-((1-(2-(貳(2_第三丁氧 -2-酮乙基)胺)-2-酮乙基)-1Η-咪唑-2-基)曱基)-8,16-二酮 -2,9,15,17-四吖廿烷-14,18,20-三羧酸三-第三丁酯
(S)-2-(3-((S)-6-胺-1-第三丁氧-1-¾ 己-2-基)腺)戊二酸二·第 三丁酯(97毫克,0_20毫莫耳),2-(((9H-芴-9-基)曱氧)羰基 胺)-6-(貳((1-(2_(貳〇第三丁氧-2-酮乙基)胺)-2-酮乙 基)-1Η-咪唑-2-基)甲基)胺)己酸(132毫克,0.12毫莫耳), EDCI(38毫克,0.20毫莫耳),HOBt(26毫克,0.20毫莫耳) 59 201034690 及DIPEA(0.30毫升)於DCM(5.0毫升)之溶液於室溫攪拌2 日。反應混合物藉拜堤以1%甲醇於DCM洗提純化,獲得 (5S,12S,16S)-5-(4-(貳((1-(2-(貳(2-第三丁氧-2-酮乙基) 胺)-2-酮乙基)-1Η-咪唑-2-基)甲基)胺)丁基)-1-(9Η-芴-9-基)-3,6,14-三酮-2-噚-4,7,13,15-四吖十八烷-12,16,18-三羧 酸三-第三丁酯(不純)呈油。 於前述產物(5S,12S,16S)-5-(4-(貳((1-(2-(貳(2-第三丁 氧-2-酮乙基)胺)-2-酮乙基)-1Η-咪唑-2-基)甲基)胺)丁 基)-1-(9Η-芴-9-基)-3,6,14-三酮-2-«号-4,7,13,15-四吖十八烷 -12,16,18-三羧酸三-第三丁酯於DMF(1.0毫升)之溶液内添 加派咬(0.50毫升)。混合物於室溫揽拌2小時。溶劑於減磨 下蒸發獲得殘餘物,藉拜堤以5%甲醇至50%曱醇於DCM洗 提純化,獲得(7S,14S,18S)-7-胺-1-(1-(2-(貳(2-第三丁氧-2-酮乙基)胺)-2-酮乙基)-1Η-咪唑-2-基)-2-((1-(2-(貳(2-第三丁 氧-2-嗣乙基)胺)-2-嗣乙基)-1 〇坐-2-基)甲基)-8,16-二酉同 -2,9,15,17-四吖廿烷-14,18,20-三羧酸三-第三丁酯(40毫 克,25%)呈白色固體。咕 NMR (400 MHz, , CDC13) 6.96 (s, 2 Η), 6.83 (d, 2 Η), 6.37 (brs, 1 Η), 6.33 (brs, 1 Η), 5.05 (s, 4 Η), 4.87 (brs, 2 Η), 4.27-4.24 (m, 2 Η), 4.18 (s, 4 Η), 4.10 (s, 4 Η), 3.88 (d,J= 15.2 Hz, 2 H), 3.62 (d, J = 15.2 Hz, 2 H), 3.14-3.12 (m, 1 H), 2.30-1.24 (m, 83 H); MS (ESI), 674.1 (M/2+H)+. 步驟3. [Re(CO)3][(7S,14S,18S)-7-胺-1-(1-(2-(貳(羧曱 基)胺)-2-酮乙基)-1Η-咪唑-2-基)-2-((1-(2-(貳(羧曱基)胺)-2- 60 201034690 酮乙基)-1Η-咪唑-2-基)甲基)-8,16-二酮-2,9,15,17-四吖廿烧 -14,18,20-三綾酸](224)。(7S,14S,18S)-7-胺-1-(1-(2-(家(2-第三丁氧-2-酮乙基)胺)-2-酮乙基)-1Η-咪唑-2-基)-2-(( 1-(2-(底(2-第二丁氧-2-網乙基)胺)-2-酬乙基)-1H-b米 0坐-2-基)曱基)-8,16-二酮-2,9,15,17-四吖廿烧-14,18,20-三叛 酸三-第三丁酯(19毫克,0.014毫莫耳)及 [NEt4]2[Re(CO)3Br3](19毫克,0.024毫莫耳)於甲醇(3 毫升) 之溶液於加壓管内於90°C攪拌3小時。蒸發去除溶劑獲得殘 餘物,殘餘物直接用於次一步驟。前述產物於TFA(3.0毫 升)/DCM(3.0毫升)之溶液於室溫攪拌隔夜。溶劑經蒸發去 除獲得粗產物,粗產物藉HPLC純化獲得 [Re(CO)3][(7S,14S,18S)-7-胺-1-(1-(2-(貳(羧甲基)胺)-2-酮 乙基)-1Η-咪唑-2-基)-2-((1-(2-(貳(羧曱基)胺)-2-酮乙 基)-111-咪唑-2-基)曱基)-8,16-二酮_2,9,15,17-四吖廿烷 -14,18,20-三羧酸](14.1毫克,82%經2步驟)呈白色固體。4 NMR (400 MHz, DMSO-i/6) 8.43 (brs, 1 Η), 8.09 (brs, 3 Η), 7.10 (s, 2 Η), 7.03 (s, 2 Η), 6.51 (brs, 1 Η), 6.31 (ά, J = 8.0 Hz, 1 Η), 6.28 (d, J= 8.4 Hz, 1 H), 5.00 (s, 4 H), 4.40-4.01 (m, 14 H), 3.70-3.64 (m, 3 H), 3.11-3.08 (m, 2 H), 2.26-1.29 (m,16 H); MS (ESI),612.8 (M+H)/2+。 實例 10 : [Re(CO)3][(7S,12S,16S)-l-(l-(羧甲基)-1Η-咪 唑-2-基)-2-((1-(羧曱基)-1Η-咪唑-2-基)甲基)-9,14-二酮 -2,8,13,15-四吖十八烷-7,12,16,18-四羧酸] 61 201034690
步驟 1 : (S)-2-(3-((S)-l-第三丁氧-5-(2,5-二酮。比咯啶-l-基氧)-l,5-二酮戊-2-基)脲)戊二酸二-第三丁酯
X0 〇
Η
(S)-5-第三丁氧-4-(3-((S)-l,5-二-第三丁氧-1,5-二酮戊-2-基) 脲)-5-酮戊酸(Kularatne, S.A.等人,分子藥物學,2009, 6, 790-800)(164毫克,0·336毫莫耳),Ν,Ν’-碳酸二丁二醯亞胺 酯(128毫克,0.50毫莫耳)及。比啶(0.10毫升)於乙腈(5.0毫升) 之溶液於室溫攪拌隔夜。於減壓下去除溶劑獲得殘餘物, 殘餘物藉拜堤以10 %至7 0 %乙酸乙酯於己烷類洗提純化,獲 得(S)-2-(3-((S)-l-第三丁氧-5-(2,5-二酮《比咯啶-l-基氧)-l,5-二酮戊-2-基)脲)戊二酸二-第三丁酯(190毫克,97%)呈白色 固體。 步驟 2. (2S,7S,llS)-2-(4-(貳((1-(2-第三丁氧-2-酮乙 基)-1Η-咪唑-2-基)甲基)胺)丁基)-7,11-貳(第三丁氧羰基)-16,16-二甲基-4,9,14-三酮-15-噚-3,8,10-三吖十七烷-1-酸 62 201034690
(S)-2-(3-((S)-l-第三丁氧_5_(2,5_二酮吡咯咬小基氧)心^二 酮戊_2_基)脲)戊二酸二-第三丁酯(丨38毫克,〇 236毫莫耳), (S)-2-胺-6-(貳((1-(2-第三丁氧-2_酮乙基唑_2_基)甲 基)胺)己酸(I27毫克,〇·237毫莫耳)&DIPEA(〇.5〇毫升)於 DMF(l.〇毫升)之溶液於室溫攪拌隔夜。於減壓下去除溶劑 獲知殘餘物,藉拜堤以1%至5〇%曱醇於DCM洗提純化,獲 得(2S’7S,llS)-2-(4-(貳((1-(2-第三丁氧-2-酮乙基)-iH-咪唑 -2-基)甲基)胺)丁基)-7,11-貳(第三丁氧羰基)-16,16-二甲基 _4,9,14_三酮-15-哼-3,8,10-三吖十七烷-1-酸(203毫克,86%) 呈白色固體。4 NMR (400 MHz, CDC13) 7.40 (brs,1 H), 6 99 (s, 2 Η), 6.79 (s, 2 Η), 6.12 (brs, 1 Η), 5.62 (brs, 1 Η), 4-67-4.28 (m, 7 Η), 3.68 (d, J= 14.0 Hz, 2 H), 3.62 (d, J = 14·0 Hz, 2 H), 2.62-2.53 (m, 2 H), 2.34-2.02 (m, 8 H), 1-83-1.42 (m,51 h); MS (ESI), 503.5 (M/2+H)+。 步驟3· [Re(CO)3][(7S,12S,16S)-l-(l-(羧甲基)-1Η-咪唑 -2-基)-2-((1-(羧甲基)-1Η-咪唑-2-基)甲基)-9,14-二酮 -2,8,13,15-四吖十八烷-7,12,16,18-四羧酸](225)。 (28,78,118)-2-(4-(貳((1-(2-第三丁氧-2-酮乙基)-111-咪唑 63 201034690 -2-基)甲基)胺)丁基)-7,11-貳(第三丁氧羰基)_16,16_二曱 基-4,9,14-三酮-15-崎-3,8,10-三吖十七烧_丨_酸(45毫克, 〇.〇448 毫莫耳)及[NEt4]2[Re(CO)3Br3](45 毫克,0.058 毫莫 耳)於曱醇(5毫升)之溶液於加壓管内於9〇它授拌4小 時。溶劑經蒸發獲得殘餘物,其係直接用於次一步驟。 前述產物於TFA(2.0毫升)/DCM(3.0毫升)之溶液於室溫 攪拌隔夜。溶劑經蒸發去除獲得粗產物,粗產物藉HPLC 純化獲得[1^((:0)3][(78,128,168)-1-(1-(羧甲基)-111-咪 哇-2-基)-2-(( 1 -(叛甲基)-111-11 米嗤-2-基)曱基)-9,14-二 _ -2,8,13,15-四吖十八烷-7,12,16,18-四羧酸](30毫克,67%經2 步驟)呈白色固體。巾 NMR (400 MHz, DMSO-A) 8.14 (d,J =7.2 Hz, 1 Η), 7.19 (ά, J = 0.8 Hz, 2 Η), 7.05 (d, /= 1.2 Hz, 2 Η), 6.37-6.34 (m, 2 Η), 4.85 (s, 4 Η), 4.58 (dd, J= 16.4, 2.8 Hz, 2 H), 4.40 (dd, J= 16.0, 2.8 Hz, 2 H), 4.22-4.04 (m, 3 H), 3.65 (t, J = 7.6 Hz, 2 H), 2.25-1.32 (m, 16 H); MS (ESI), 995.3 M+ ° 實例 11 : [Re(CO)3][(7S,12S,16S)-l-(l-(2-(貳(幾甲基) 胺)-2-酮乙基)-1Η-咪唑-2-基)-2-((1-(2-(貳(羧甲基)胺)-2-酮 乙基)-1Η-咪唑-2-基)甲基)-9,14-二酮-2,8,13,15-四吖十八烷 _7,12,16,18-四羧酸] 64 201034690 Ο
r
Θ _Re(CO)3 步驟1· (S)_2_胺_6_(似(1-(2-(束(2_第三丁氧_2_嗣乙基) 胺)-2-酮乙基)_ΐΗ·咪唑-2-基)甲基)胺)己酸
2-(((9HU-基)曱氧)羰基胺)-6-(家((1 -(2_(武(2_第三丁氧 -2-酮乙基)胺)_2-酮乙基)_1H-咪唑-2-基)甲基)胺)己酸(19〇 毫克,〇_173毫莫耳)及哌啶(0_50毫升)於DMF(0.5〇毫升)之溶 液於室溫攪拌1小時。溶劑於減壓下蒸發獲得粗產物。粗產 物藉拜堤SP4以5%至50%甲醇於DCM之梯度方法純化獲得 (S)-2-胺-6-(貳((1-(2-(貳(2-第三丁氧-2-酮乙基)胺)-2-¾乙 基HH-咪唑-2-基)甲基)胺)己酸(0.120克,79%)。巾NMR (400 MHz,DMSO-A) 6.92 (s, 2 H),6.76 (s, 2 H),5.01 (s,4 H),4.32 (s,2 Η), 4.31 (s,2 Η), 3_92 (s,4 Η), 3.44 (s,4 H), 3.01-2.99 (m, 1 Η), 2.30 (t, J= 7.2 Hz, 2 H), 1.60-1.57 (m, 2 H), 1.43 (s, 18 H), 1.35 (m, 18 H). 1.30-1.12 (m, 4 H); MS 65 201034690 (ESI), 439.4 (M/2+H)+。 步驟2. (28,78,118)-2-(4-(武((1_(2_(武(2_第三丁氧_2_酬 乙基)胺)-2-嗣乙基)-lHH2-基)曱基)胺)丁基)_7,n_武 (第三丁氧羰基)-16,16-二甲基_4,9,14_三酮_15_哼_3,8,1〇_三 〇丫十七烧-1-酸。
(s) 2 ^3-((sH-f — T
酮戊2’基)脲)戊二酸(82毫力,〇 14毫莫耳),⑻_2_胺各( (((2 (武(2-第二了氧_2__乙基)胺)_2_酮乙基 土)曱基)胺)己酸(98毫克’ 〇 u毫莫耳)&DipEA⑴5〇毫 ;DMF(2.〇毫升)之溶液於室溫攪拌隔冑。於減壓下去除 =知殘餘物’藉拜堤以1%至4()%甲醇於洗提純化 獲件(2S,7S,11S)1(4他(1_(2侦(2_第三丁氧_2_酮乙^ ,)山2綱乙基)_1Hh2d甲基)胺)丁基)_7,m(第三 氧&基)·16,16-二曱基·4,9,14_三酮 _15_u,8,ig三。丫十 S夂(125毫克,84%)呈白色固體。㈣(现),^ (M/2+H)+。 66 201034690
步驟 3. [Re(CO)3][(7S,12S,16S)-l-(l-(2-(武(幾甲基) 胺)-2-酮乙基)-1Η-σ米0坐-2-基)-2-((1-(2-(武(叛甲基)胺)_2__ 乙基)-1Η-51米0坐-2-基)甲基)-9,14-二酮-2,8,13,15-四。丫十八烧 -7,12,16,18-四羧酸](226)。(28,78,118)-2-(4-(貳((1_(2_(武(2_ 第三丁氧-2-酮乙基)胺)_2_酮乙基)-1Η-咪唑-2-基)曱基)胺) 丁基)-7,11-貳(第三丁氧羰基)-16,16-二甲基-4,9,14-三酮 -15-哼-3,8,10-三吖十七烷-1-酸(54毫克,0.040毫莫耳)及 [NEt4]2[Re(CO)3Br3](47毫克,0.060毫莫耳)於甲醇(5 毫升) 之溶液於加壓管内於9〇°C攪拌4小時。溶劑經蒸發獲得殘餘 物,殘餘物直接用於次一步驟。前述產物於TFA(2.0毫 升)/DCM(3.0毫升)之溶液於室温攪拌隔夜。蒸發去除溶劑 獲得粗產物,粗產物藉HPLC純化獲得標題化合物(44.8毫 克,91%經2步驟)呈白色固體。4 NMR (400 MHz,DMSO-c/6) 8.17 (d, 7.6 Hz, 1 Η), 7.11 (d, J = 1.2 Hz, 2 H), 7.03 (d, J =1.2 Hz, 2 H), 6.37-6.33 (m, 2 H), 5.02 (s, 4 H), 4.40-3.98 (m, 15 H), 3.65 (t, J = 7.6 Hz, 2 H), 2.25-1.32 (m, 14 H); MS (ESI), 613.3 (M+H)/2+。 藉前述方法選用適當反應劑製備之額外化合物包括如 下實例14至2〇。 實例 12 : (7S,22S,26S)-9,16,24-三酮-l-(喹啉-2-基)-2-(喹啉-2-基甲基)-2,8,17,23,25-五吖廿八烷-7,22,26,28-四 羧酸 67 201034690
Ο _ ,π Ο 實例 13 : (7S,22S,26S)-9,16,24-三¾小(吡咬l基)_ 2十比心2-基甲基)-2,8,l7,23,25-五n丫廿八烷_7,22,26,28_四 羧酸
ο ο 實例 14 : (22S,26S)-9,16,24-三酮-2-(吡啶-2-基甲基)-2,8,17,23,25-五吖廿八烷-1,7,22,26,28-五羧酸
實例 15 : (7S,22S,26S)-1-(1-羧甲基)-1Η·咪唑-2-基)-2- ((3_(幾甲基)-3Η-吼略-2-基)甲基)-9,16,24-三酮-2,8,17,23,25-五吖廿八烷-7,22,26,28-四羧酸 68 201034690
實例 16 : (19S,23S)-l-(l-(羧甲基)-1Η-咪唑-2-基)-2-((1-(羧甲基)-1Η-咪唑-2-基)甲基)-13,21-二酮-2,14,20,22-四吖 廿五烷-19,23,25-三羧酸]
實例 17: (78,118,268)-26-(4-(貳((1-甲基-111-咪唑-2-基) 甲基)胺)丁基)-7,11-貳(第三丁氧羰基)-2,2-二甲基-4,9,17,24-四酮-3-哼-8,10,16,25-四吖廿七烷-27·酸
69 201034690 基於1,4,7,10-四吖環十二烷-1,4,7,10-四乙酸(DOTA)結 合螯合體可製備其它化合物。此等基於DOTA之螯合體可用 於螯合顯像金屬包括但非限於釔、錙、鎵及銦。基於DOTA 之螯合體可如前文摘述製備,探勘DOTA中之一個酸基鏈接 至其它R基。基於DOTA之化合物實例包括但非限於此處Μ 為 Υ、Lu、Ga、或 In ;及η為 0至 20 : co2h ο Λ
h〇2C k
co2h Ν. Ν C02H ό〔 κ〕 H02C^N N^co# 〇 又
h〇2C κ 實例 18. (7S,22S,26S)-1-(1-甲基-1Η-咪唑-2-基)-2-((1-甲基-1H-咪唑-2-基)曱基)-9,16,24-三酮-2,8,17,23,25-五吖 廿八烷-7,22,26,28-四羧酸]之1^((:0)3錯合物。 70 201034690
〇 Ο (S)-2-(3-((S)-l-第三丁氧 _6_(8_(2,5_ 二酮吡咯 〇定 _丨_ 基 氧)-8-酮辛醯胺)-1_酮己_2_基)脲)戊二酸二-第三丁醋(〇·356 克’ 0.48毫莫耳),化合物13之化合物⑺16克,〇 48毫莫耳) 及DIPEA(l.〇t升)於DMF(5.0毫升)之溶液於室溫攪拌隔 伙。条發去除溶劑獲得殘餘物,殘餘物藉拜堤以DCM/Me〇H 洗提純化獲得(7S,11S,26S)-26-(4_(^((iHih-_^-2-1:) 甲基)胺)丁基)-7,11-貳(第三丁氧羰基)_2,2_二甲基 -4,9,17,24-四酮-3-噚-8,10,16,25-四吖廿七烷 _27_ 酸(81 毫 克 ’ 18%)。MS (ESI), 481 (M/2+H)+。 (7S,llS,26S)-26-(4-(武((1_ 甲基_1Η_„米唑_2_基)甲基)胺) 丁基)-7,11 -貳(第三丁氧羰基)_2,2_二甲基_4,9,丨7,24_四酮 -3-噚-8,10,16,25-四吖廿七烷_27_酸(72毫克,〇〇75毫莫耳) 及[NEt4]2[Re(CO)3Br3](72毫克,0.094毫莫耳)於甲醇(4毫升) 之/谷液於加壓管於95 C授拌4小時。溶劑經蒸發獲得殘餘 物,殘餘物直接用於次一步驟。前述產物於TFA/DCM之溶 液於室溫擾拌隔夜。蒸發去除溶劑獲得粗產物,粗產物藉 HPLC純化獲得[Re(CO)3][(7s,22S,26S)小(1_ 甲基_m咪唑 -2-基)-2-((1-甲基-1H-咪唑-2-基)甲基)-9,16,24-三酮 71 201034690 -2,8,17,23,25-五#廿八烧-7,22,26,28-四羧酸](4.0毫克)呈白 色固體。1H NMR (400 MHz,DMSO-A) 8.08 (d,/= 8.0 Hz, 1 H), 7.72 (t, j= 5.4 Hz, 1 H), 7.24 (d, /= 1.2 Hz, 2 H), 7.05 (d, 1.2 Hz, 2 H), 6.31 (d, J = 8.4 Hz, 1 H), 6.28 (d, J = 8.0 Hz, 1 H), 4.69 (d, J= 16.8 Hz, 2 H), 4.54 (d,/= 16.8 Hz, 2 H), 4.28-4.23 (m, 1 H), 4.11-4.03 (m, 2 H), 3.78 (s, 6 H), 2.97-2.92 (m; 2 H), 2.26-2.20 (m, 2 H), 2.11 (t, J = 7.2 Hz, 2 H)> L" (t, J = 7.6 Hz, 2 H), 1.90-1.20 (m, 24 H); MS (ESI), 531.8 (M/2+H)+ ° 式I化合物與銖、鉻或其它金屬之其它螯合錯合物可藉 前文舉例說明之方法製備。由於系收縮,銖與錯具有類 似之尺寸及反舰。如此目銖具有多種不錢射性之安定 同位素@錯合物可做出相對應之放射性錯錯合物表現的 良好合成與賴研賴型。如此齡當提供鍊錯合物時, 也製備錯錯合物,及反之亦然。 下表1實例係藉前述方 ^ 万去製備,或經早離或如前文就保 護基之說明於原位進行。
72 201034690
實例 化合物 R e Ζ f W g NRaRb 19 Η 4 - 0 - 0 DIMA 20 Η 4 〇 6 0 COOH 人々 Η 4 DQK 21 Η 4 〇 6 0 COOH '儿 Ν 士、 Η 4 M-DQK 22 Η 4 〇 6 0 COOH Ύ、 4 DPK 23 Η 4 〇 6 O COOH 人乂A Η 4 M-DPK 24 Bul 4 〇 、/Ά 6 Ο COOH 人乂A Η 4 PAMA 25 Η 4 〇 ΥΉ义, 6 O COOH 人乂A Η 4 PAMA 26 Η 4 0 ΥΉ义, 6 0 COOH "V、 4 M-PAMA 27 Bu* 4 〇 6 Ο COOH Ύ、 4 t-Bu-PAM A 28 Η 4 〇 、/Ά 6 O COOH 人乂A Η 4 PAMA 29 Bul 4 Η 6 O COOH \又 νΛ1、 Η 4 t-Bu-DCM I 30 Η 4 〇 ^νΛ1- 6 Ο COOH 、ν、 4 DCMI 31 Η 4 〇 1人/、 6 Ο COOH Η 4 M-DCMI 32 Η 4 - 0 - 0 M-DCMI 33 Η 4 〇 、/Ά 10 - 0 DCMI 34 Η 4 〇 Υ· 口人/、 10 - 0 M-DCMI 73 201034690
實例 化合物 R e Ζ f W g NRaRb 35 Η 4 〇 ΥνΛ1、 Η 10 - 0 M-DCMI 36 Bul 4 .Λ 6 0 COOH Η 4 DIMA 37 Η 4 νΛ Η 6 0 COOH Ά乂/、 4 M-DIMA 38 Η 4 〇 10 - 0 M-DIMA 39 Η 4 〇 6 0 6 PAMA 40 Η 4 〇 •νΆ Η 5 - 0 M-DCMI 41 Η 4 〇 ΥΉ义, 6 0 6 M-DPK 42 Η 4 〇 Η 10 0 0 M-CIMA A 43 Η 4 0 ΥΉ义, 10 0 0 t-Bu-CIM AA 44 Bul 4 0 10 - 0 t-Bu-TIM 45 Η 4 〇 υΆ Η 10 0 M-TIM 46 Η 4 〇 0 0 M-DCMI 47 Η 4 νΛ 0 2 M-DCMI 48 Η 4 〇 •νΆ Η 0 -ch(nh2)- 4 M-DCMI 74 201034690
實例 化合物 R e Z f w g NRaRb 49 Η 4 〇 、/νΛ1、 Η 0 -CH(NH2)- 4 M-TIM 50 Bul 4 〇 0 -CH(NH2)- 4 t-Bu-CIM AA 51 Bul 4 〇 0 -CH(NHFmoc)- 4 t-Bu-CIM AA 52 Η 4 〇 、,νΛλ Η 0 -CH(NH2)- 3 M-TIM 53 Η 4 - 0 - 0 M-PAMA 54 Η 4 0 、/.νΛλ Η 0 -CH(NHFmoc)- 4 DOTA 55 Bul 4 〇 0 -CH(NHFmoc)- 4 DOTA 56 - 4 〇 0 -CH(NHFmoc)- 4 M-DOTA 57 - 4 Ο Η 0 -CH(NH2)- 4 M-DOTA 58 Bu 2 γΑ' 0 co2h 0 - 4 DCMI 59 Η 2 0 co2h 0 - 4 M-DCMI 60 Bu1 2 V 丫' 0 co2h 0 - 4 t-Bu-TIM 61 Η 2 γΑ' 0 co2h 0 - 4 M-TIM 62 Bu 2 0 co2h 4 - DOTA 75 201034690
實例 化合物 R e Ζ f w g NRaRb 63 Η 2 γΆ' 0 co2h 4 - M-DOTA 64 4 hV Η νη2 4 - DOTA 65 4 hV Η ΝΗ2 4 - M-DOTA 66 Bul 4 NHC(0)(CH2)n n - DOTA 67 Η 4 NHC(0)(CH2)n n - M-DOTA 68 Bul 2 C(0)NH(CH2)n n - DOTA 69 Η 2 C(0)NH(CH2)n n - M-DOTA 備註··上表中有關NRaRb基之縮寫係對應如下結構式:
76 201034690
縮寫 結構式 縮寫 結構式 M-DCMI η〇2^ν^νν g J \㊉ -\—f-——;M(CO)3 r/) H02CvN J t-Bu-TIM ·Ν?Ν -ϊ-J $、Ni 〇 M-TIM 〇<^〇Η H0Y^f 0 f=\ 〇ΐί^ΝγΝ';:Μ(〇〇)3 —卜// / 〇Xn^oh HO^J 0 〇 PAMA α -1— VH 〇 M-PAMA Q 1 N-- —-;M(CO)3 Sr° 0 DPK Q -丨V M-DPK 0, έ T \© N——;M(CO)3 DIMA 』9ν -\—Ν J M-DIMA r=\ -ΝγΝχ -\—N-~~—M(CO)3 yj DQK -j-N^ "CO 77 201034690
一般生物學 新製備之通式結構式5類似物係使用psMA陽性 +LnCap細胞以3 nM濃度於人攝護腺癌細胞結合檢定7刀析 篩檢。此篩檢結果驗證化合物是否對PSMA(+)細胞具有專 一性結合。對PSMA(+)細胞具有專一性結合之化合物於對 PSMA之已知抑制劑,N-[N-[(S)-1,3_二羧丙基]胺曱酿 基]-S-3-碘-L-酪胺酸(DCIT)之競爭結合檢定分析中進一步 評估,及算出IC50值。 試管内初步篩檢 LNCaP及PC3人攝護腺癌細胞係得自美國種型培養收 集會(American Type Culture Collection),馬里蘭州洛克維。 LNCaP細胞係維持於補充1 〇〇/〇胎牛血清(FBS)之RPMI-1640 培養基。放射性標記化合物之結合及與冷衍生物競爭結合 至LNCaP細胞係根據已知程序經適當修改進行。細胞以約 4xl05細胞/孔接種於12孔孔板,及於化合物添加前於37艺 78 201034690 / I氧化化培育11峡養48小時。製備各種Glu_ 、丨物及稀釋於含0.5%胎牛血清(BSA)組合3nM 1231 DOT(已知之抑㈣丨)之W清細胞培養基。 經由未使用 試驗化合物料1231⑽了敎總結合作用。歧於室溫培 養1小時由孔板移出細胞及移轉至伊本朵夫管。樣品於脈 xg微離^ 15&。培養基經抽吸,丸粒藉分散於新製檢定分 析介質接者微離心洗務兩次。於自動化丫計數器内計算細胞 丸粒數目測定Ϊ⑽了之細胞結合作用。非專一性結合係 測定為與2 uM未經放射性標記化合物或2_鱗曱基戊二酸 (ΡΜΡΑ)培養後與細胞結合之計數值。關鍵性對照化合物顯 示於下圖。
生物檢定分析
組織生物分布結果係與試管試驗資料符合一致,驗證 於LNCaP (PSMA陽性)腫瘤有顯著吸收。結果也顯示高度專 一性,於PC3(PSMA陰性)腫瘤中之活性極低。 使用N-[N-[(S)-1,3-二羧丙基]胺甲醯基]-S-3-碘-L-酪胺 酸(1-131-DCIT)相對於「冷」錯合物進行生物評估,證實為 快速首次篩檢,接著為劑量曲線來測定準確IC5〇值。該系列 化合物之領先者具有IC5G值小於50nM。領先系列之活體試 驗資料驗證高度親和力,具有3% ID/克積聚於LNCaP腫瘤 79 201034690 及具有高度專一性,LNCaP對PC3之比超過15比1。 NAALADase檢定分析 NAAG之結合經測定,PSMA測定如下:(a)反應混合物 之製備:經由組合LNCaP細胞溶解產物(200微克)與600微升 反應緩衝液(反應緩衝液:50 mM Tris-HCl, pH 7.4, 20 mM CoCl2, 32 mMNaCl)製備反應混合物。允許混合物於使用前 於37°C前培養3分鐘。(b)經放射性標記NAAG溶液之製備: 經由使用反應緩衝液(1 mM)將1微升100 mM備用材料稀釋 至100微升而製備經放射性標記之NAAG備用材料。(c)檢定 分析:檢定分析之進行係添加6微升ImM NAAG(對ΙμΜ終 濃度)以 1,000,000 CPM 之 3H-NAAG(100 微升 1 mM NAAG+10微升3H-NAAG(l(^Ci)挑釁至該反應混合物。用 於競爭結合研究添加PMPA[何種濃度]及將所得溶液於37 °C培養30分鐘。於特定時間點經由移出1〇〇微升反應混合物 及添加等量冰冷0.25 Μ KH2PO4, pH 4_3而中止反應。約半 量經緩衝之混合物載荷至250毫克AG 50W-X4陽離子交換 管柱(200至400篩號,H+形式,使用前以去離子水溶脹樹 脂)。已載荷之管柱使用50微升1:1反應緩衝液 /0·25ΜΚΗ2ΡΟ4洗滌及以3M KC1 (1·5毫升)洗提。結合至管 柱之放射性標記濃度係使用閃爍計數器測定及100微升洗 提劑(稀釋1:6)來減少淬熄。 治療性處理 本化合物可用於抑制NAALADase供治療性處理。可接 受NAALADase處理之疾病包括疼痛及感官糖尿病性神經 80 201034690 病變、神經元受損及攝護腺癌、精神分裂、結腸直腸癌、 發炎、肌萎縮性脊側索硬化、或糖尿病性神經病變。本化 合物也可用作為止痛藥。此等治療性處理之模型化指南可 參考Goodman & Gilman治療學之藥理基礎,麥克羅西爾公 司,第10版,2001年、藥物前調配及配方:自候選藥物選 擇至商用劑型之實用指南,CRC公司,2001年,及藥學賦 形劑手冊,阿法A出版公司,第5版,2005年。 圖中參考若干化合物用於比較目的。該等比較性化合
81 201034690 比較例 號碼 結構式 4 r=\ 、::,c(c〇)3 ηΛο Μ/ν3 τ0 / 丨 ηΤηΛ«5η 5 α Η 1 \® 一·Νί—-;Tc(CO)3 ηΛο 0 cooh ^γ< 丫 Η ^ U η〇^^Λ〇η 0 0 6 V0H 广 ν人 \。/ Η Η ΗΤΝηΑη2Η 放射性藥品實例之組織分布 此處製備之多種化合物及錯合物評估其組織分布,於 某些情況下與比較化合物比較。第1、3、4及5圖以圖解顯 示若干此等資料。第6圖為放射性影像顯示實例6化合物之 99mTc錯合物之組織生物分布。 相當物 雖然已經舉例說明若干實施例,但須瞭解未悖離如下 申請專利範圍界定之廣義面相中之技術,可根據技藝界尋 常技巧於其中做出變化及修改。 82 201034690 本揭示並未限於本案所述 ^ 玫特疋實施例之術語。如熟諳 技藝人士顯然易知,可未條雜甘1^ 離其精趟及範圍做出多項修改 及變化。除了此處列舉者之外,熟諳域人士由前文說明 顯然易㈣人於本揭示範圍之功能Μ方法及組成物。此 等修改及變化意圖落入於隨附之申請專利範圍之範圍内。 本揭不射_之巾請專利範圍各項連同此等中請專利範 圍應有的相當物之完整範_限。須瞭解本揭示並未限於 特定方法、試劑、化合物、組成物或生物系統,當然可有 變化。也須瞭解此處使用之術語僅供敘述特定實施例而非 意圖為限制性。 此外,當揭示内容之特徵及面相係就驗㈣組群描述 時,熟諳技藝人士須瞭解該揭示也係就該MarkushM群之任 何個別成員或成員亞群描述。 热諳技藝人士瞭解用於任何及全部目的特別係就提供 書面說明,此處揭示之全部範圍也涵蓋任何及全部可能的 其小範圍及其小範圍之組合。任何引述之範圍皆容易瞭解 為充分描述該範圍及允許該範圍分解成至少相等的對半、 三分之一、四分之一、五分之一、十分之一等。至於非限 制性實例’此處討論之各個範圍方便分解成下三分之_、 中三分之一、及上三分之一等。亦如熟諸技藝人士瞭解, 全部用詞諸如「至多」、「至少」、「大於」、「小於」等包括 所引用之數目且係指隨後可分解成如前文討論之小範圍之 該等範圍。最後如熟諳技藝人士瞭解一個範圍包括各個個 別成員,包含於該範圍内列舉的第一數目及最末數目。 83 201034690 本說明書中述及之全部公告案、專利申請案、已核發 之專矛丨案、及其它文件係以引用方式併入此處彷彿各個個 別a 口案、專利申請案'已核發之專利案、或其它文件全 文係特別地且個別地指示其全文係以引用方式併入此處。 以引用方式併入此處之上下文中所含定義係排除至與本揭 示之定義矛盾之程度。 其它實施例係陳述於下列申請專利範圍。 【阐式簡單說明】 第1圖為實例3化合物之99mTc錯合物於LNCaP異種移植 小鼠之組織分布圖,以%DP〇表示。 第2圖顯示比較性及說明性根據式I化合物對P S Μ A蛋 白質之競爭結合曲線。 第3圖為實例8化合物之99mTc錯合物之組織分布圖,以 %ID/克表示。 第4圖為實例7化合物之99mTc錯合物之組織分布圖,以 °/〇ID/克表示。 第5圖為99mTc錯合物於LNCaP異種移植小鼠之組織生 物分布之比較圖,以%ID/克表示。 第6圖為影像示例顯示於各個時間間隔及根據若干實 施例實例6化合物之99mTc錯合物於LNCaP異種移植小鼠之 組織生物分布。 【主要元件符號說明】 (無) 84
Claims (1)
- 201034690 七、申請專利範圍: κ 一種式I化合物、其藥學上可接受之鹽或溶劑合物:其中 R為Η、銨離子、烷基銨離子、鹼土金屬離子、稀 土金屬離子、或烧基; W 為一鍵結、-NHC(O)-、-CH(NH2)-、 -NH-C(0)-NH-、-C(0)-NH-、-C(0)-NH-CH(COOH)-、 -0-(CH2)n-0-(CH2)n- 、 -(CH2)nO(CH2)nO(CH2)n-、 -CH(NHFmoc)-; Z 為一鍵結、-CO(O)-、-NH-、-NHC(O)-、 -NH-C(0)-NH-、-NH-C(0)-(CH2)n-、-NH-C(0)-CH(NH2)-、 -C(0)-NH-CH(COOH)- ;或-NH-C(0)-C6H4-(CH2)n-NH-; NRaRb為下式螯合基:85 201034690V-N, R'OOC ,或 以為^!、CrC8烷基、銨離子、烷基銨離子、或鹼金 屬離子或驗土金屬離子; Rv為烷基; e為0至15之整數; f為0至15之整數; g為0至15之整數;及 η為0至10之整數; 但限制條件為若NRaRb為:則當W為鍵結時,Z非為鍵結、-C(0)-NH_、或 -NHC(O)-;及當Z為鍵結時,W非為鍵結、-C(0)-NH-、 或-NHC(O)- 〇 86 201034690 2.如申請專利範圍第1項之化合物,其中rv為甲基、乙基、正 丙基'異丙基、正丁基、異丁基、或第三丁基。 3·如申請專利範圍第2項之化合物,其中!^為甲基。 4. 如申請專利ϋ圍第i項之化合物,其中各個Ri分別為h或第 三丁基。 5. 如申請專利範圍第4項之化合物,其中Rt為η。 6. 如申請專利範圍第1項之化合物,其中e為自〇至4之整數,f 為自〇至12之整數,及g為自〇至6之整數。 7. 如申請專利範圍第丨項之化合物,其中W為_c(〇)-NH-。 8·如申請專利範圍第1項之化合物,其為:87 20103469088 201034690其藥學上可接受之鹽或溶劑合物; e為自0至10之整數; f為自0至12之整數; g為自0至12之整數;及 η為自0至10之整數。 9. 如申請專利範圍第1項之化合物,其中Ζ為-NH-C(O)-。 10. 如申請專利範圍第1項之化合物,其中Z為 -C(0)-NH_CH(C00H)-。 11. 如申請專利範圍第1項之化合物,其中Z為 -nh-c(o)-ch(nh2)-。 89 201034690 12. —種錯合物,包含金屬及如申請專利範圍第1項之化合 物。 13. 如申請專利範圍第12項之錯合物,其中該金屬為Re、Tc、Y、 Lu、Ga、In、或 Cu。 14. 如申請專利範圍第12項之錯合物,其中該金屬為放射性核 種。 15. 如申請專利範圍第14項之錯合物,其中該金屬為錄-99m、 銖-186、或銖-188。 16. 如申請專利範圍第12項之錯合物,其中NRaRb為 Rt〇2C飞 /~y 厂C02Rt Μ Μ—I—[ΝΠ ;及 該金屬係選自於由Y、Ga、Lu、In及Cu所組成之組 群。 17.如申請專利範圍第12項之錯合物,其為:-CO :CO 90 201034690co 0HC4rco /!、、、、91 201034690其藥學上可接受之鹽或溶劑合物; Μ為 Re、Tc、Y、Lu、Ga、In、或 Cu ; e為自0至10之整數; f為自0至12之整數; g為自0至12之整數;及 η為自0至10之整數。 92 201034690 18. —種藥學配方,包含如申請專利範圍第1至17項中任一項 之化合物、其藥學上可接受之鹽類或溶劑合物及藥學上 可接受之賦形劑。 19. 一種顯像病人體内一部位之方法,包含下列步驟:對一 病人投予診斷上有效量之如申請專利範圍第1至18項中 任一項之化合物、其藥學上可接受之鹽或溶劑合物,及 獲得該病人之該部位之影像。20. —種顯像選自於脾組織、腎組織及攝護腺專一性膜抗原 (PSMA)表現性腫瘤組織中之組織之方法,包括讓該組織接 觸包含放射性金屬及包含下式基團之化合物:其藥學上可接受之鹽或溶劑合物之一錯合物。 21.如申請專利範圍第20項之方法,其中該組織為攝護腺專一 性膜抗原(PSMA)表現性腫瘤組織。 93
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12022608P | 2008-12-05 | 2008-12-05 | |
US18034109P | 2009-05-21 | 2009-05-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW201034690A true TW201034690A (en) | 2010-10-01 |
Family
ID=42076951
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW098141532A TW201034689A (en) | 2008-12-05 | 2009-12-04 | CA-IX specific radiopharmaceuticals for the treatment and imaging of cancer |
TW098141536A TW201034690A (en) | 2008-12-05 | 2009-12-04 | Technetium-and rhenium-bis (heteroaryl) complexes and methods of use thereof for inhibiting PSMA |
TW098141540A TW201034691A (en) | 2008-12-05 | 2009-12-04 | Technetium-and rhenium-bis(heteroaryl) complexes and methods of use thereof |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW098141532A TW201034689A (en) | 2008-12-05 | 2009-12-04 | CA-IX specific radiopharmaceuticals for the treatment and imaging of cancer |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW098141540A TW201034691A (en) | 2008-12-05 | 2009-12-04 | Technetium-and rhenium-bis(heteroaryl) complexes and methods of use thereof |
Country Status (13)
Country | Link |
---|---|
US (1) | US8211401B2 (zh) |
EP (4) | EP2373621A2 (zh) |
JP (4) | JP2012511024A (zh) |
CN (3) | CN102272102A (zh) |
AU (3) | AU2009322167B2 (zh) |
BR (3) | BRPI0922779A8 (zh) |
CA (3) | CA2745958A1 (zh) |
ES (2) | ES2574514T3 (zh) |
HU (2) | HUE030681T2 (zh) |
PL (2) | PL2389361T3 (zh) |
RU (3) | RU2539565C2 (zh) |
TW (3) | TW201034689A (zh) |
WO (1) | WO2010065902A2 (zh) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8524200B2 (en) | 2002-09-11 | 2013-09-03 | The Procter & Gamble Company | Tooth whitening products |
WO2009026177A1 (en) | 2007-08-17 | 2009-02-26 | Purdue Research Foundation | Psma binding ligand-linker conjugates and methods for using |
EP2227784B1 (en) | 2007-12-28 | 2014-07-16 | Exini Diagnostics AB | System for detecting bone cancer metastases |
US8562945B2 (en) | 2008-01-09 | 2013-10-22 | Molecular Insight Pharmaceuticals, Inc. | Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof |
JP2011509304A (ja) | 2008-01-09 | 2011-03-24 | モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド | 炭酸脱水酵素ixの阻害剤 |
US8211402B2 (en) | 2008-12-05 | 2012-07-03 | Molecular Insight Pharmaceuticals, Inc. | CA-IX specific radiopharmaceuticals for the treatment and imaging of cancer |
RU2539565C2 (ru) * | 2008-12-05 | 2015-01-20 | Моликьюлар Инсайт Фармасьютикалз, Инк. | Са-ix специфические радиофармпрепараты для лечения и визуалазиции злокачественных опухолей |
WO2010147965A2 (en) | 2009-06-15 | 2010-12-23 | Molecular Insight Pharmaceuticals, Inc. | Process for production of heterodimers of glutamic acid |
US9951324B2 (en) | 2010-02-25 | 2018-04-24 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
JP6275484B2 (ja) * | 2010-12-06 | 2018-02-07 | モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド | Psma標的化デンドリマー |
TR201910084T4 (tr) | 2011-08-05 | 2019-08-21 | Molecular Insight Pharm Inc | Radyoaktif-etiketli prostat spesifik membran antijen inhibitörleri. |
US10011632B2 (en) | 2011-08-22 | 2018-07-03 | Siemens Medical Solutions Usa, Inc. | PSMA imaging agents |
EP2785712B1 (en) * | 2011-11-30 | 2019-05-01 | The Johns Hopkins University | Homomultivalent and heteromultivalent inhibitors of prostate specific membrane antigen (pmsa) and uses thereof |
WO2013103813A1 (en) | 2012-01-06 | 2013-07-11 | Molecular Insight Pharmaceuticals | Metal complexes of poly(carboxyl)amine-containing ligands having an affinity for carbonic anhydrase ix |
FR2989085A1 (fr) * | 2012-04-05 | 2013-10-11 | Commissariat Energie Atomique | Radiotraceurs, procedes de preparation et applications |
EA201590783A1 (ru) * | 2012-11-15 | 2015-11-30 | Эндосайт, Инк. | Конъюгаты для доставки лекарственных средств и способы лечения заболеваний, вызванных клетками, экспрессирующими psma |
BR112015016585B1 (pt) * | 2013-01-14 | 2021-02-02 | Molecular Insight Pharmaceuticals | compostos radiofarmacêuticos baseados em triazina, complexos de metal e composição farmacêutica compreendendo os referidos complexos |
JP6434496B2 (ja) * | 2013-04-22 | 2018-12-05 | アッヴィ・インコーポレイテッド | チアゾールおよびその使用 |
CN105636924B (zh) | 2013-10-18 | 2018-08-07 | 德国癌症研究中心 | 前列腺特异性膜抗原(psma)的标记的抑制剂,它们作为显影剂和用于治疗前列腺癌的药剂的用途 |
CN105792855A (zh) * | 2013-10-18 | 2016-07-20 | 分子制药洞察公司 | 使用spect/ct分析进行癌症分期的方法 |
EP2993171A1 (en) * | 2014-09-04 | 2016-03-09 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Method for the production of 18F-labeled PSMA-specific PET-tracers |
US9956305B2 (en) | 2014-09-08 | 2018-05-01 | Molecular Insight Pharmaceuticals, Inc. | Organ protection in PSMA-targeted radionuclide therapy of prostate cancer |
US10188759B2 (en) | 2015-01-07 | 2019-01-29 | Endocyte, Inc. | Conjugates for imaging |
NZ739770A (en) | 2015-09-30 | 2019-07-26 | Deutsches Krebsforsch | 18f-tagged inhibitors of prostate specific membrane antigen (psma) and their use as imaging agents for prostate cancer |
KR101639599B1 (ko) * | 2015-11-09 | 2016-07-14 | 서울대학교산학협력단 | 펩타이드 싸이오우레아 유도체, 이를 포함하는 방사성 동위원소 표지 화합물 및 이를 유효 성분으로 함유하는 전립선암 치료 또는 진단용 약학적 조성물 |
EP3192810A1 (en) * | 2016-01-14 | 2017-07-19 | Deutsches Krebsforschungszentrum | Psma binding antibody and uses thereof |
CN105510511B (zh) * | 2016-01-23 | 2017-04-12 | 河北科技大学 | 一种2‑氨基丁醇对映异构体的hplc分离检测方法 |
US11458213B2 (en) * | 2016-03-22 | 2022-10-04 | The Johns Hopkins University | Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer |
CA3028978A1 (en) | 2016-06-23 | 2017-12-28 | Cornell University | Double targeted constructs to affect tumor kill |
US10806806B2 (en) | 2016-06-23 | 2020-10-20 | Cornell University | Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies |
CA3036754A1 (en) | 2016-10-27 | 2018-05-03 | Progenics Pharmaceuticals, Inc. | Network for medical image analysis, decision support system, and related graphical user interface (gui) applications |
CN110612126B (zh) | 2017-04-05 | 2023-11-03 | 康奈尔大学 | 可用于成像和抗肿瘤治疗的具有可调的药代动力学的三功能构建体 |
CN111032632B (zh) * | 2017-05-30 | 2024-04-12 | 约翰霍普金斯大学 | 用于前列腺癌的腔内放射疗法的前列腺特异性膜抗原靶向的高亲和力剂 |
WO2019136349A2 (en) | 2018-01-08 | 2019-07-11 | Progenics Pharmaceuticals, Inc. | Systems and methods for rapid neural network-based image segmentation and radiopharmaceutical uptake determination |
US10973486B2 (en) | 2018-01-08 | 2021-04-13 | Progenics Pharmaceuticals, Inc. | Systems and methods for rapid neural network-based image segmentation and radiopharmaceutical uptake determination |
CA3090495A1 (en) * | 2018-02-06 | 2019-08-15 | The Johns Hopkins University | Psma targeted radiohalogenated urea-polyaminocarboxylates for cancer radiotherapy |
RU2692126C1 (ru) * | 2018-02-13 | 2019-06-21 | Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) | Способ получения производного мочевины с хелатным центром, тропного к простат-специфичному мембранному антигену для связывания технеция-99м/рения для диагностики/лечения рака предстательной железы |
US20210276971A1 (en) * | 2018-06-20 | 2021-09-09 | The Research Foundation For The State University Of New York | Triazamacrocycle-derived chelator compositions for coordination of imaging and therapy metal ions and methods of using same |
CN112638919A (zh) * | 2018-08-30 | 2021-04-09 | 日本医事物理股份有限公司 | 放射性咪唑并噻二唑衍生物化合物 |
CN113272859A (zh) | 2019-01-07 | 2021-08-17 | 西尼诊断公司 | 用于平台中立性全身图像分段的系统及方法 |
US11534125B2 (en) | 2019-04-24 | 2022-12-27 | Progenies Pharmaceuticals, Inc. | Systems and methods for automated and interactive analysis of bone scan images for detection of metastases |
CA3134745A1 (en) | 2019-04-24 | 2020-10-29 | Progenics Pharmaceuticals, Inc. | Systems and methods for interactive adjustment of intensity windowing in nuclear medicine images |
US11544407B1 (en) | 2019-09-27 | 2023-01-03 | Progenics Pharmaceuticals, Inc. | Systems and methods for secure cloud-based medical image upload and processing |
US11900597B2 (en) | 2019-09-27 | 2024-02-13 | Progenics Pharmaceuticals, Inc. | Systems and methods for artificial intelligence-based image analysis for cancer assessment |
US11564621B2 (en) | 2019-09-27 | 2023-01-31 | Progenies Pharmacenticals, Inc. | Systems and methods for artificial intelligence-based image analysis for cancer assessment |
US11386988B2 (en) | 2020-04-23 | 2022-07-12 | Exini Diagnostics Ab | Systems and methods for deep-learning-based segmentation of composite images |
US11321844B2 (en) | 2020-04-23 | 2022-05-03 | Exini Diagnostics Ab | Systems and methods for deep-learning-based segmentation of composite images |
US11721428B2 (en) | 2020-07-06 | 2023-08-08 | Exini Diagnostics Ab | Systems and methods for artificial intelligence-based image analysis for detection and characterization of lesions |
TW202207241A (zh) | 2020-07-06 | 2022-02-16 | 瑞典商艾西尼診斷公司 | 用於偵測及表徵化病變之基於人工智慧的影像分析系統與方法 |
EP4326246A1 (en) * | 2021-04-23 | 2024-02-28 | Wisconsin Alumni Research Foundation | Psma-targeting ligands with optimal properties for imaging and therapy |
WO2023057411A1 (en) | 2021-10-08 | 2023-04-13 | Exini Diagnostics Ab | Systems and methods for automated identification and classification of lesions in local lymph and distant metastases |
WO2023239829A2 (en) | 2022-06-08 | 2023-12-14 | Progenics Pharmaceuticals, Inc. | Systems and methods for assessing disease burden and progression |
US20240285248A1 (en) | 2023-02-13 | 2024-08-29 | Progenics Pharmaceuticals, Inc. | Systems and methods for predicting biochemical progression free survival in prostate cancer patients |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2730457A (en) | 1953-06-30 | 1956-01-10 | Ncr Co | Pressure responsive record materials |
US2730456A (en) | 1953-06-30 | 1956-01-10 | Ncr Co | Manifold record material |
US2800457A (en) | 1953-06-30 | 1957-07-23 | Ncr Co | Oil-containing microscopic capsules and method of making them |
US3625214A (en) | 1970-05-18 | 1971-12-07 | Alza Corp | Drug-delivery device |
US4272398A (en) | 1978-08-17 | 1981-06-09 | The United States Of America As Represented By The Secretary Of Agriculture | Microencapsulation process |
US4906474A (en) | 1983-03-22 | 1990-03-06 | Massachusetts Institute Of Technology | Bioerodible polyanhydrides for controlled drug delivery |
JPS6131056A (ja) | 1984-07-25 | 1986-02-13 | K Baiorojikaru Sci Lab:Kk | ホイッピングクリームの製造方法 |
WO1988001213A1 (en) | 1986-08-18 | 1988-02-25 | Clinical Technologies Associates, Inc. | Delivery systems for pharmacological agents |
JP3051497B2 (ja) | 1991-05-17 | 2000-06-12 | 株式会社第一ラジオアイソトープ研究所 | スルファニルアミド誘導体のテクネチウム錯体をもちいる放射性診断剤 |
US6359120B1 (en) | 1991-10-29 | 2002-03-19 | Bracco International B.V. | Rhenium and technetium complexes containing a hypoxia-localizing moiety |
HUT66220A (en) * | 1991-12-10 | 1994-10-28 | Dow Chemical Co | Bicyclopolyazamacrocyclophosponic acids, their complexes and conjugates for use as contrast agents, and processes for their preparation |
ES2200617B1 (es) * | 2001-01-19 | 2005-05-01 | Almirall Prodesfarma, S.A. | Derivados de urea como antagonistas de integrinas alfa 4. |
EP1389460A1 (en) * | 2001-05-24 | 2004-02-18 | Kureha Chemical Industry Co., Ltd. | Cxcr4-antagonistic drugs comprising nitrogen-containing compound |
DE10127581A1 (de) * | 2001-05-29 | 2003-01-02 | Schering Ag | CDK inhibitorische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel |
DE10135355C1 (de) | 2001-07-20 | 2003-04-17 | Schering Ag | Konjugate makrocyclischer Metallkomplexe mit Biomolekülen und deren Verwendung zur Herstellung von Mitteln für die NMR- und Radiodiagnostik sowie die Radiotherapie |
US20030100594A1 (en) | 2001-08-10 | 2003-05-29 | Pharmacia Corporation | Carbonic anhydrase inhibitor |
WO2003053932A1 (fr) * | 2001-12-21 | 2003-07-03 | Tohru Koike | Complexes de zinc capables de pieger des substances portant des substituants anioniques |
CA2372731A1 (en) * | 2002-02-22 | 2003-08-22 | Claudiu T. Supuran | Oligo-amine/oligo-carboxy sulfonamides |
AU2003213819C1 (en) | 2002-03-11 | 2010-03-04 | Molecular Insight Pharmaceuticals, Inc. | Technetium-dipyridine complexes, and methods of use thereof |
DE10231799B4 (de) * | 2002-07-10 | 2006-10-05 | Schering Ag | Verwendung von perfluoralkylhaltigen Metallkomplexen als Kontrastmittel im MR-Imaging zur Darstellung von Intravasalen Thromben |
KR100863667B1 (ko) * | 2002-09-11 | 2008-10-15 | 가부시끼가이샤 구레하 | 아민 화합물 및 그 용도 |
US7833734B2 (en) | 2002-11-26 | 2010-11-16 | Institute Of Virology Of The Slovak Academy Of Sciences | CA IX-specific inhibitors |
CA2506983C (en) | 2002-11-26 | 2010-03-30 | Institute Of Virology | Ca ix-specific inhibitors |
US7291631B2 (en) * | 2003-04-11 | 2007-11-06 | Genzyme Corporation | CXCR4 chemokine receptor binding compounds |
EP1692099A1 (en) | 2003-12-12 | 2006-08-23 | Oy Juvantia Pharma Ltd | Somatostatine receptor subtype 1 (sstr1) active compounds and their use in therapy |
AU2005215510A1 (en) * | 2004-02-12 | 2005-09-01 | Molecular Insight Pharmaceuticals, Inc. | Technetium-and rhenium-bis(heteroaryl) complexes, and methods of use thereof |
KR101149124B1 (ko) * | 2004-03-10 | 2012-05-25 | 가부시끼가이샤 구레하 | 아민계 염기성 화합물과 그의 용도 |
WO2006080993A1 (en) | 2004-12-08 | 2006-08-03 | Purdue Research Foundation | Novel cationic metal complex radiopharmaceuticals |
WO2006137092A1 (en) * | 2005-06-23 | 2006-12-28 | Supuran Claudiu T | Fluorescent sulfonamide derivatives having carbonic anhydrase inhibiting activity and their use as theapeutic and diagnostic agents |
FR2890657B1 (fr) * | 2005-09-15 | 2007-11-09 | Commissariat Energie Atomique | Procede d'obtention de complexes de lanthanides hautement luminescents. |
WO2007058322A1 (ja) * | 2005-11-18 | 2007-05-24 | Ono Pharmaceutical Co., Ltd. | 塩基性基を含有する化合物およびその用途 |
US20090044345A1 (en) | 2006-02-06 | 2009-02-19 | Gunther Schlingloff | Use of Metal Complex Compounds as Oxidation Catalysts |
EP2030971B1 (en) | 2006-06-20 | 2011-10-12 | Ishihara Sangyo Kaisha, Ltd. | Pest control agent containing novel pyridyl-methanamine derivative or salt thereof |
EP2055705A4 (en) * | 2006-07-31 | 2014-08-20 | Ono Pharmaceutical Co | COMPOUND WITH A CYCLIC GROUP BOUND BY A SPIRO BINDING THEREOF AND APPLY THEREOF |
CN101594886A (zh) * | 2006-08-29 | 2009-12-02 | 分子制药洞察公司 | 偶合到用于成像表达肽酶的组织和器官的肽酶结合部分的放射影像部分 |
EP3335736B1 (en) * | 2006-11-08 | 2020-12-30 | Molecular Insight Pharmaceuticals, Inc. | Heterodimers of glutamic acid |
US20100111858A1 (en) * | 2007-01-19 | 2010-05-06 | Howard Carol P | Diangostic and Therapeutic Cyclooxygenase-2 Binding Ligands |
WO2008098056A2 (en) * | 2007-02-06 | 2008-08-14 | Epix Pharmaceuticals, Inc. | High relaxivity chelates |
WO2009076434A1 (en) | 2007-12-12 | 2009-06-18 | Molecular Insight Pharmaceuticals, Inc. | Inhibitors of integrin vla-4 |
US8562945B2 (en) * | 2008-01-09 | 2013-10-22 | Molecular Insight Pharmaceuticals, Inc. | Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof |
JP2011509304A (ja) * | 2008-01-09 | 2011-03-24 | モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド | 炭酸脱水酵素ixの阻害剤 |
US20100098633A1 (en) | 2008-09-25 | 2010-04-22 | Molecular Insight Pharmaceuticals, Inc. | Selective seprase inhibitors |
RU2539565C2 (ru) * | 2008-12-05 | 2015-01-20 | Моликьюлар Инсайт Фармасьютикалз, Инк. | Са-ix специфические радиофармпрепараты для лечения и визуалазиции злокачественных опухолей |
US8211402B2 (en) | 2008-12-05 | 2012-07-03 | Molecular Insight Pharmaceuticals, Inc. | CA-IX specific radiopharmaceuticals for the treatment and imaging of cancer |
-
2009
- 2009-12-04 RU RU2011127467/04A patent/RU2539565C2/ru not_active IP Right Cessation
- 2009-12-04 JP JP2011539757A patent/JP2012511024A/ja not_active Ceased
- 2009-12-04 AU AU2009322167A patent/AU2009322167B2/en active Active
- 2009-12-04 EP EP09765209A patent/EP2373621A2/en not_active Withdrawn
- 2009-12-04 ES ES13195617.9T patent/ES2574514T3/es active Active
- 2009-12-04 HU HUE09775429A patent/HUE030681T2/en unknown
- 2009-12-04 HU HUE13195617A patent/HUE029940T2/en unknown
- 2009-12-04 BR BRPI0922779A patent/BRPI0922779A8/pt active Search and Examination
- 2009-12-04 CN CN2009801538786A patent/CN102272102A/zh active Pending
- 2009-12-04 CN CN2009801538771A patent/CN102272101A/zh active Pending
- 2009-12-04 AU AU2009322164A patent/AU2009322164B2/en active Active
- 2009-12-04 BR BRPI0922840A patent/BRPI0922840A2/pt active IP Right Grant
- 2009-12-04 PL PL09775429T patent/PL2389361T3/pl unknown
- 2009-12-04 ES ES09775429.5T patent/ES2595128T3/es active Active
- 2009-12-04 CN CN200980153722.8A patent/CN102272100B/zh active Active
- 2009-12-04 EP EP09775430A patent/EP2373622A2/en not_active Withdrawn
- 2009-12-04 RU RU2011127462/04A patent/RU2539584C2/ru active
- 2009-12-04 TW TW098141532A patent/TW201034689A/zh unknown
- 2009-12-04 JP JP2011539752A patent/JP2012511022A/ja active Pending
- 2009-12-04 CA CA2745958A patent/CA2745958A1/en not_active Abandoned
- 2009-12-04 JP JP2011539755A patent/JP5220203B2/ja active Active
- 2009-12-04 CA CA2745955A patent/CA2745955C/en active Active
- 2009-12-04 BR BRPI0922839A patent/BRPI0922839A2/pt not_active IP Right Cessation
- 2009-12-04 EP EP09775429.5A patent/EP2389361B1/en active Active
- 2009-12-04 US US12/631,337 patent/US8211401B2/en active Active
- 2009-12-04 CA CA2745918A patent/CA2745918C/en active Active
- 2009-12-04 AU AU2009322171A patent/AU2009322171A1/en not_active Abandoned
- 2009-12-04 TW TW098141536A patent/TW201034690A/zh unknown
- 2009-12-04 RU RU2011127468/04A patent/RU2532912C2/ru active
- 2009-12-04 WO PCT/US2009/066836 patent/WO2010065902A2/en active Application Filing
- 2009-12-04 TW TW098141540A patent/TW201034691A/zh unknown
- 2009-12-04 EP EP14155382.6A patent/EP2759535A1/en not_active Withdrawn
- 2009-12-04 PL PL13195617.9T patent/PL2706057T3/pl unknown
-
2014
- 2014-07-15 JP JP2014145241A patent/JP5856247B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW201034690A (en) | Technetium-and rhenium-bis (heteroaryl) complexes and methods of use thereof for inhibiting PSMA | |
US20210283279A1 (en) | Use of labeled inhibitors of prostate specific membrane antigen (psma), as agents for the treatment of prostate cancer | |
RU2749399C2 (ru) | Простатический специфический мембранный антиген-таргетные высокоаффинные средства для эндорадиотерапии рака предстательной железы | |
US20070166227A1 (en) | Crowned dithiocarbamate metal complexes and methods for their use | |
JP6275484B2 (ja) | Psma標的化デンドリマー | |
US6359111B1 (en) | Opioid receptor targeting | |
JP2021513979A (ja) | エバンスブルー誘導体の化学結合体ならびに前立腺癌を標的とするための放射線療法および造影剤としてのその使用 | |
WO2010065899A2 (en) | Technetium-and rhenium-bis(heteroaryl)complexes and methods of use thereof | |
JP2012503670A (ja) | 選択的セプラーゼ阻害剤 | |
HUE035739T2 (en) | Triazine-based radiopharmaceuticals and radiological imaging agents | |
JP2022527821A (ja) | Hsp90結合コンジュゲート及びその製剤 | |
JP2021521106A (ja) | Hsp90標的化コンジュゲート及びその製剤 | |
CA3205844A1 (en) | Ligands and their use | |
JP6087386B2 (ja) | 造影剤としてのn−アルコキシアミド抱合体 | |
Sivapackiam et al. | Synthesis, molecular structure, and validation of metalloprobes for assessment of MDR1 P-glycoprotein-mediated functional transport | |
CN116217505A (zh) | 用于诊断或治疗表达前列腺特异性膜抗原癌症的新型标记靶向剂 |